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Abstract
A small percentage of patients with sickle cell disease (SCD) have experienced an
increase in life span by 10 years, while others with the same disease continue to die
prematurely. The purpose of the study was to evaluate whether or not regional location
was a barrier to care for adults with SCD in relation to emergency department visits and
health outcomes at 16 and 21 years after the approval of hydroxyurea therapy as
treatment. Secondary data were sourced and a retrospective quantitative correlational
design was used to examine the effect of hydroxyurea treatment approval on emergency
department visits and mortality (dependent variables) with changes in the regions for
Northeast, Midwest, South, and West (independent variables). Insurance status, age,
gender, and income level (covariables) were employed to describe the population. ChiSquare analysis was used to examine the association of the variables and sample sizes
provided by the HCUP datatsets; Nationwide Inpatient Sample (NIS) 2006 (n=67,214),
NIS 2011 (n=80,040), Nationwide Emergency Department Sample (NEDS) 2006
(n=164,698), and NEDS 2011 (n=215,296). The results of the analysis revealed a
significant association between regional location, emergency department visits, and
deaths among SCD patients. The implications for social change include improvements in
health and health outcomes regionally, with adult SCD education for health care
providers and patients on SCD treatment protocols. Adults with SCD might possibly
benefit from this study with improvements in health and health outcomes for all regions
once the barrier to care and specific areas are identified.
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Chapter 1: Topic of the Study
Introduction
Sickle cell disease (SCD) is a genetic blood disorder affecting over 100,000
African Americans in the United States and is one of more than 6,500 rare diseases in the
United States recognized by the National Institute of Health (NIH) (Medline Plus: Rare
Diseases, 2016). There is mandated newborn testing for SCD in the United States and the
number of infants testing positive is over 500 annually (Addis, 2010). The
pathophysiology of the disease involves the premature development of red blood cells,
resulting in a sickle shape which causes occlusions as it flows through the small blood
vessels. The results of the occlusions are known as vaso-occlusive crisis and hemolysis,
which lead to severe pain in the joints, back, and anatomical areas of the body with major
organs. The major organs that could be affected include the brain (stroke), spleen (splenic
infarction), lungs (acute chest syndrome), penis (priapism), kidneys (kidney failure), and
gallbladder (cholecystitis) (Addis, 2010). The most severe phenotypes of SCD are
Thalassemia β 0 and HbSS; African Americans predominantly have the HbSS phenotype
which has been associated with health complications and premature mortality (Serjeant,
2013).
Of the more than 6,500 rare diseases, the Food and Drug Administration (FDA)
has approved over 200 preventive drugs for treatment; hydroxyurea was the drug
approved by the FDA in 1990 to treat SCD (Developing Products for Rare Diseases,
2016). Improvements in treatment regimens have been credited with increasing the life
span by 10 years for males and females; however only a small percentage of patients
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have experienced the extended life span. Notably, there has been a 3% decrease in the
mortality rate of children, which means that the adult population could increase placing
more demands on the healthcare system for accessibility, quality care, and resources
(Lanzrros, Carroll, & Haywood, 2013). Therefore, there is a need to evaluate the adult
SCD population to identify barriers to care. Overcoming the barriers would be the next
step for improving healthcare and outcomes for SCD.
Not only is SCD detrimental to the health and lifestyle of the affected population,
but there have been barriers to care identified for adults with sickle cell disease which
contributes to the complications (Vallerand & Nowak, 2010). Research has shown that
barriers to obtaining care would be insurance status and deficiencies in the number of
physicians specializing (hematology) in the field (Bediako & Moffitt, 2011; Treadwell,
Barreda, Kaur, & Gildengorin, 2015). The barriers to care when seeking medical care
include lack of accessibility and stigmas (drug abuser, drug addict) attached to the disease
(Voskaridou et al., 2010).
This research study examined how the health of African American adults living
with SCD could be affected according to residential region in the United States. High
emergency department services usage, lack of accessibility to care, ineffective pain
management and treatments (hydroxyurea use), and mortality rates could be indicators of
regional barriers to care (Odesina et al., 2010). The social changes that could occur from
the results of this study include the development of effective SCD transition programs,
accessible comprehensive sickle cell centers for adults, and improved SCD educational
programs.
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The transition programs from pediatric to adult care have not provided an
environment for adults to receive the quality of care that was standard in the pediatric
setting (DeBaum & Telfair, 2012). Additional potential social changes could be
improvements in the quality-of-life, health outcomes, and life span with the provision of
accessible and quality health care. Chapter 1 is a discussion of how living in different
regions of United States could affect the health outcomes of adults with SCD. The
literature review reiterated the impact of emergency visits, treatments, and mortality on
the lives of patients with SCD.
Background
Emergency room services were used by 90% of adults with SCD for pain
management and associated complications from organ damage (Ballas, Gupta, & AdamsGraves, 2012; Brousseau, Owens, Mosso, Panepinto, & Steiner, 2010; Woods et al.,
1997). Adults have a higher usage of emergency services than children (Ballas et al.,
2012). The reasons for the high usage of emergency services would include lack of
accessibility to care, ineffective pain management, and severity of disease (Haywood,
Tanabe, Naik, Beach, & Lanzkron, 2013). The lack of accessibility to care and ineffective
management of the disease occurred during the transition period from a child with SCD
to an adult with SCD (Anderson, Bellot, Senu-Oke, & Ballas, 2014; DeBaum & Telfair,
2012).
Pain is the predominant symptom in sickle cell disease making pain management
a priority focus for treatment regimens (Haywood et al. 2013). Three types of pain
sensations have been identified in SCD; vaso-occlusive crisis (VOC), hemolysis, and
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neuropathic pain (Smith, 2014). Vaso-occlusive crisis and hemolysis cause pain, damage
to organs, and could lead to life-threatening complications and death (Booker, Blethyn,
Wright, & Greenfield, 2006). Neuropathic pain is experienced in sickle cell disease
patients with exposure to extreme temperatures such as hot and cold (Jones et al., 2005).
The pain is described as numbness and tingling associated with a pins and needle type
sensation (Ballas, 2007). The standard analgesic for severe pain management is opioids
(Smith, 2014). Hemolysis and vaso-occlusive crisis should be managed using preventive
treatments to improve decreasing the need for high doses of analgesics, major organ
damage, and premature mortality (Voskaridou et al., 2010). The preventive treatment
used in SCD is hydroxyurea which has been associated with decreased episodes of
painful crisis, organ damage, and mortality rates (Colella et al., 2012; Smith et al., 2011).
Overall, the use of preventive treatments and effective pain management are needed to
improve the health of SCD patients.
The lifespan of sickle cell patients is 43 years for males and 48 years for females
(Tanabe et al., 2010). Complications of lung disease from organ damage have been
shown to be the cause of death for 65% of adults with SCD (Lanzrros et al., 2013).
Researchers have shown in a study from 1979 to 2005 that the median age of death in
SCD males was 38 years and females were 42 years which was a decrease in the life span
from 42 years for males and 48 years for females noted in 1990 (Lanzrros et al., 2013).
According to Voskaridou et al. (2010) the lifespan of SCD patients has increased by 10
years. The differences in research results could imply that the variations in life spans
occur with changes in accessibility and treatment regimens in the various regions of the
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United States. In this case, regional location in the United States could be a barrier to
care.
There was a gap in the literature that did not address the use of treatments and
mortality in correlation to different geographic locations in the United States. Regional
standards of care, accessibility, and physician performance in treating SCD have not been
investigated as a possible barrier to care in SCD. The regional standards of care and
physician performance could be examined using indicators which include use of
emergency services (accessibility), changes in the number of emergency visits (disease
management), and mortality rates in the years after the approval of hydroxyurea. The
study was needed to identify significant barriers that could be corrected with appropriate
resource allocation and SCD education. The lives of patients with SCD could improve
physically and socially from the provision of quality care and improvements in health
outcomes.
Problem Statement
There is high usage of emergency department services by adults with SCD which
could be from the inability to secure the services of a private physician, inadequate pain
management, and lack of a maintenance treatment regimen (Andermariam et al.,2014).
The lack of hydroxyurea use among adult SCD patients has created a notable difference
in outcomes when compared to the adult patients using hydroxyurea. Sickle cell patients
using hydroxyurea as a routine treatment regimen could experience decreased painful
episodes, minimal incidents of organ damage, and a longer life span by 10 years
(Voskaridou et al., 2010). The problem lies in the need to identify and prevent barriers to
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care that could hinder the use of hydroxyurea. According to Yawn et al. (2014),
hydroxyurea use should be included as the standard of care for most patients with SCD.
Included in the standards of care for SCD routine maintenance are an effective analgesic
protocol, hydration, and hydroxyurea (Yawn et al., 2014). Thereby, with the acceptance
of hydroxyurea by healthcare providers as a standard of care for SCD, a higher
percentage of the population could benefit from the effects.
I designed this study to explore the effects of hydroxyurea approval for SCD
treatment by the FDA, mortality rates (mortality), and accessible health care (emergency
department utilization) in the four regions of the United States. The effects were
examined using numerical data and statistical analysis in a quantitative correlational
research design. Emergency visits were considered a predictor of disease management,
severity of disease, and accessibility to care. Sickle cell patients require health services
urgently due to the unpredictable onset of VOC not responding to the prescribed and
recommended daily routine treatments (Tanabe et al., 2010). Studies (Davis, Gergen, &
Moore, 1997; Telfair, Hague, Etienne, Tang, & Strasser, 2003) reported there were
differences for SCD adults geographically in health service utilization, access to care, and
pediatric mortality. McGann and Ware (2011) reported that hydroxyurea compliance was
low in SCD patients even though a decrease in organ damage, episodes of painful crisis,
and mortality has been associated with hydroxyurea use, which is approved by the FDA
for SCD treatment. The physician not prescribing the drug and patient noncompliance
with taking the drug were the reasons given for low usage of hydroxyurea (Smith et al.,
2011; Ware, 2010). As a result, deficits in accessible resources and quality care

7
impacting the use of hydroxyurea could occur from a lack of sickle cell education and
available physicians to provide care.
Accessibility to health care resources and quality care has been shown to be a
deficit for SCD patients that could contribute to a decreased quality-of-life and shortened
life span. Sickle cell patients have a high use of emergency services and inpatient hospital
services for pain management and treatment for complications from organ damage
caused by manifestations of the disease along with increased healthcare costs (Brousseau
et al., 2010; Wolfson, Schrager, Khanna, Coates, & Kipke, 2012). High inpatient
hospitalization and emergency department visit rates for adults were associated with the
use of government sponsored insurances and longer travel distances (Brousseau et al.,
2010; Wolfson et al., 2012). Private physicians that provide SCD quality care may not
accept government sponsored insurances because of low payment fees, decreasing the
availability of specialty care (Jan et al., 2013). Jan et al. (2013) published that for SCD
young adults and adolescents the type of hospital and specialty of the provider were
significant for improved health outcomes. The literature did not address how living in
different geographical regions of the United States could affect resources, treatments, and
mortality for sickle cell patients.
Purpose of the Study
A retrospective correlational quantitative design with secondary data was used to
describe the relationship between regional geographical location and health outcomes
from accessibility and treatments. The data was collected from 46 states and represent the
four regions of the United States (Northeast, Midwest, South, and West). The data was
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used to explore the effects of regional location (independent variable) on accessibility
indicated by use of emergency services (dependent variable), disease management
(dependent variable), and mortality rates (dependent variable) 16 and 21 years after
hydroxyurea treatment was approved by the FDA. Improvements in treatment regimens
could be indicated with decreased emergency service usage, increased use of
hydroxyurea, and decreased mortality rates consistently in all regions.
Research Questions and Hypotheses
The information that was provided while responding to the hypotheses and
research questions consisted of the effects of regional location on health care
accessibility, treatment, and mortality. The number of emergency visits (accessibility),
hydroxyurea approval and its effects 16 and 21 years postFDA approval on mortality
rates and the number of emergency visits (disease management) were identified for each
region. The information was used to answer how geographical location affects
accessibility, health outcomes, and mortality of adults with sickle cell disease. The null
and alternate hypotheses reflected whether there was a statistical significance for the
association between accessibility, treatments, mortality, and geographical location of
adults with SCD.
RQ1: Is there a significant association between emergency services use
(accessibility) among adults with SCD and regional geographic location (Northeast,
Midwest, South, and West) represented by 46 states in the United States from the HCUP
database.
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H01: There is not a significant association between emergency services use
(accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
Ha1: There is a significant association between emergency services use
(accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
RQ2: Is there an association between the number of emergency department visits
(disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD
treatment?
H02: There is no significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
Ha2: There is a significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
RQ3: Is there an association between hydroxyurea approval and SCD mortality
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in
2006 (16 years later) and 2011 (21 years later)?
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H03: Hydroxyurea approval does not have a significant association on mortality
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South,
and West) in 2006 (16 years later) and 2011 (21 years later).
Ha3: Hydroxyurea approval has a significant association on mortality rates in
adults with SCD in relation to geographic location (Northeast, Midwest, South, and
West) in 2006 (16 years later) and 2011 (21 years later).
Theoretical and Conceptual Framework
The socioecological model was used as the theoretical framework for the study
along with data from Healthcare Cost and Utilization Project (HCUP) to determine the
effects of internal and external factors that could be associated with sickle cell disease
health outcomes; such as, the region where the patient lives, effect of FDA approval of
hydroxyurea treatment for SCD, mortality, and geographical location to explain the
differences in disease presentations among patients with the same genotype. The
differences in outcomes recognized by the socioecological mode could encompass
insurance status, income level, and availability of resources representative of local, state,
and federal allocations. The history and additional information on the concepts for the
socioecological model are discussed in Chapter 2. The concepts from the model were
applicable to SCD level of knowledge in patients and physicians for preventive therapies.
For example, patients with SCD should avoid extreme weather conditions and
temperatures (hot, cold, and windy). With the application of the concepts to SCD
barriers to care, the quality of care in SCD could improve with increased knowledge,
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along with health care and health outcomes. Even more, the utilization of health services
and annual costs for treating SCD would likely decrease.
The conceptual framework for the study was the Donabedian theory of quality
care (DTQHC). Donabedian introduced the model in 1966 to evaluate and focus on
health outcomes, treatments, and healthcare utilization (Kobayashi, Takemura, and
Kanda, 2011). Descriptions were given for the three dimensions of quality health care in
the last revision of the model in 1987: health, recipients of care, and providers of care
(Kobayashi et al., 2011). It is important to realize that quality care is needed for sickle
cell patients to improve their quality of life by decreasing incidents of comorbidities,
provision of effective pain management, and decrease rates for premature mortality.
Outcomes for the effects of the regional location (independent variable) were
identified and evaluated using the concepts of the model with the examination of
emergency visits (accessibility), effect of hydroxyurea treatment for SCD by the FDA on
the mortality and emergency visits (disease management) [dependent variables].
Utilization of the model created an environment for identifying and evaluating outcomes
and effects of the indicators. The Donabedian model is discussed with more detail in
Chapter 2. The research question related to the quality healthcare framework was how
does regional location could affect health outcomes, treatment, and mortality in adults
with SCD? The documentation and knowledge that increased mortality, poor disease
management, and increased emergency services usage could be indicators for the need of
resources and education in SCD. Thereby, public officials on the state and federal levels
could use the information to allocate resources for the care of SCD patients.
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Nature of the Study
A quantitative retrospective correlational method was used to obtain a numerical
description of the population in order to describe the association between the variables to
include regions, Northeast, Midwest, South, and West (independent variable), and the
effect of FDA approval of hydroxyurea treatment on emergency visits and mortality
(dependent variables) with statistical analysis. An examination of the variables regionally
described whether the independent variable influenced the dependent variables and the
correlation of emergency department use (accessibility), mortality rates, and emergency
department visits (disease management) 16 and 21 years after hydroxyurea was approved
for SCD treatment by the FDA. The datasets were obtained from HCUP; data for HCUP
is collected and processed annually and sponsored by AHRQ (Agency for Healthcare
Research and Quality, 2012). Two datasets represented in HCUP are the Nationwide
Inpatient Sample (NIS) 2006 and 2011 and the Nationwide Emergency Department
Sample (NEDS) 2006 and 2011 collected from 46 states representative of the four
regions (Northeast, Midwest, South, and West) in the United States. The datasets were
available from 2006 to 2013 and include information such as emergency room visits,
diagnosis, geographical location, age, disposition, insurance status, and date of death.
Definitions
Acute chest syndrome: A diagnosis used in sickle cell disease when a combination
of symptoms exists, such as fever, productive cough, difficulty breathing and decreased
oxygen levels; along with a chest x-ray reading of acute infiltrate (Paul, Castro,
Aggarwal, & Oneal, 2011).
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Analgesic: a drug that relieves pain (Merriam-Webster’s Learner’s Dictionary,
n.d.).
Cholecystitis: inflammation of the gallbladder (Mayo Clinic, 1998-2016).
HbSS: the most severe SCD phenotype which originates from inheriting two
copies of the HbS mutation (Centers for Disease Control and Prevention, 2014).
Hydroxyurea: a drug used to treat SCD by preventing the formation of sickleshaped red blood cells by stimulating the increased production of fetal hemoglobin
(McGann & Ware, 2011, p. 2).
Neuropathic: chronic pain caused by damage to nerves (Niscola, Sorrentino,
Scaramucci, Fabtitiis, & Cianciulli, 2009, p. 470).
Phenotypes: the genetic and epigenetic properties observed in an organism
(Ballas, 2011, p. 512).
Priapism: an involuntary long lasting penile erectile dysfunction (Azik et al.,
2012, p. 270).
Splenic infarction: oxygen supply to the spleen is interrupted (Owusu-Ofori &
Hirst, 2013, p. 3).
Thalassemia β0: an inherited lifelong disease that is characteristically similar to
SCD with milder symptoms (Serjeant, 2013, p. 2).
Assumptions
Assumptions that were made for this study included:
•

Adequate information from the NIS 2006, NIS 2011, NEDS 2006, and
NEDS 2011 datasets to complete the study.
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•

A sufficient sample size to validate the study results.

•

Appropriate variances to determine associations and significance of
regional location.

•

The study findings could be generalizable to adults (21 years and older)
with SCD HbSS living in the United States.
Scope and Delimitations

Emergency visits were chosen for this study to indicate that there could be lack of
accessibility to care from a private physician or comprehensive sickle cell disease
facility. Severity of disease with ineffective pain management was an additional indicator
for seeking care in the emergency department. The indicators for the effect of
hydroxyurea (treatment) approval by the FDA 16 and 21 years later were the number of
emergency visits and the mortality rates. Health care and health outcomes (mortality)
were indicators of quality care which would be dependent on physician and patient SCD
knowledge, along with effective pain management regimens to decrease episodes of VOC
and hemolysis (analgesics and hydroxyurea); thereby decreasing organ damage and life
threatening complications, and premature death.
The population identified in this study were male and female adults (21 years and
older) living in the United States with SCD HbSS. The International Classification of
Diseases, Ninth Revision, Clinical Classification (ICD 9-CM) billing codes that were
used for identification were 282.60 (nonspecific SCD), 282.61 (SCD without crisis), and
282.62 (SCD with crisis). The codes were documented within the first five diagnoses
fields of the medical record. The age group of the population represented adults that had
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transcended from pediatric care to adult care and were confronted with adult barriers to
care. Sickle cell disease HbSS has an occurrence of one in 300 to 500 African Americans
and the phenotype is predominant in the race; Hispanics have an occurrence of one in
36,000 for HbSS. Other less severe forms of SCD have been identified in people of
Mediterranean and Asian descent. Specifically, the barriers to care for adults with SCD
HbSS should be examined and provisions made to improve quality of care.
The Health Belief Model (HBM) was not used as a theoretical framework in the
study. The focus of the study was the identification of external barriers to care and the
effects from lack of resources and knowledge. The concepts of the HBM focus on patient
disease knowledge, reasons to control and prevent illness, perceptions of the illness, selfefficacy, considerations for barriers and benefits to care, and self-care management
(Glanz, Rimer, & Viswanath, 2008). Statements made pertaining to the results of the
study were generalizable to adults (21 years and older) with SCD HbSS living in the
United States.
Limitations
The results of the study are limited to the relationship and correlation of the
independent variables (regions) and dependent variables (number of emergency visits and
mortality rates 16 and 21 years after hydroxyurea approval). Covariates for external
validity (gender, insurance status, and income level) for emergency visits and mortality
were used to describe the population demographically. Internal validity for accuracy of
information on number of emergency visits, mortality rates, and geographical location
could affect the results of the study.
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Significance
Factors affecting the health outcomes of SCD patients could be identified in this
study, such as quality of care, premature death, and accessibility to care. Regional
locations that could be lacking in resources and knowledge were identified by increased
use of emergency services and mortality rates which could be representative of the lack
of accessibility and low rates of hydroxyurea treatment after approval by the FDA. Health
outcomes could be improved with the insight provided from the study results;
justification would be provided for resource allocation to deficient areas and educational
needs of healthcare professionals and patients. Social change could potentially be
implicated with the use of SCD standardized treatment protocols to equalize medical
treatment of SCD patients, identifying and recommending ways to increase accessibility
to care, and to determine healthcare needs for resource allocation.
Sickle cell disease treatment standards were developed by the World Health
Organization in 1984 (revised in 2012), and the NIH: National Heart Lung and Blood
Institute in 1984 (revised 2002) for the improvement of pain management and health
outcomes (Moussavou, Vierin, Eloundou-Orima, Mboussou, & Keita, 2004).
Manifestations of SCD impose symptoms and complications on the patients that require
frequent inpatient hospital admissions and a high use of emergency services which
increases health care expenditures. It was published in studies by (Brousseau et al., 2010;
Wolfson et al., 2012) that long travel times to obtain medical care and the use of
government issued insurance plans (Medicaid, Medicare) by adults with SCD were
associated with increased inpatient hospitalizations and high emergency department
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visits. At the same time, increased use of emergency services use could be directly related
to the inability of SCD patients to obtain a private physician that will accept the lower
fees paid by government issued insurances. The costs of healthcare incurred by adults
with SCD were reported by Woods et al., (1997) over a 2 year time frame to be $59
million with government issued insurance plans used by two-thirds of the patients. The
estimated costs of SCD health care expenditures for emergency visits and inpatient
admits was reported in several studies (Andemariam et al., 2014; Epstein, Yuen, Riggio,
Ballas, & Moleski, 2006) as $2.4 billion in 2006 with pain management as the underlying
complaint. Adults with SCD have increased medical expenses when compared to children
with SCD. A study was published by Kauf, Coates, Huazhi, Mody-Patel, and Hartzema
(2009) showing the monthly costs for adult (50 to 64 years) SCD healthcare was $1382
and children (0 to 9 years) was $892. The costs of healthcare for SCD patients are
increasing because the patients are living longer. The burden of increasing medical
expenses could be decreased with the implementation of effective pain management and
treatment regimens which would be reflected in a reduction in inpatient hospital
admissions and emergency department visits. For the most part, sickle cell patients could
benefit from the use of standardized protocols throughout the United States to improve
health outcomes and equalize the use of evidence-based treatments.
Summary
Chapter 1 provided an introduction to the pathophysiology of SCD, complications
of the disease, barriers to care, and health outcomes. The problem statement addressed
the focus of the study and directed the design of the study and research questions.
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Assumptions and limitations were discussed along with the theoretical and conceptual
frameworks using the concepts to improve the quality of care and identify the barriers to
care. The knowledge gap was identified for regional location to be evaluated as barrier to
care and the correlation of emergency visits and how FDA approval of hydroxyurea for
SCD treatment could affect emergency visits and mortality rates.
Chapter 2 contains the literature review which is sectioned by the prevailing
themes found in the literature; emergency visits, pain management, treatments,
complications, and mortality. Barriers to care were identified for many areas including
insurance status, location (rural versus urban), lack of accessibility, income level, and
stigmas. Geographical regions in the United States had not been evaluated as a barrier to
care, which could affect emergency visits, treatment, and mortality rates in the reviewed
literature creating a gap in knowledge.
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Chapter 2: Literature Review
Introduction
Sickle cell disease HbSS is the most common phenotype among people of African
descent and the population group for this research (Public Health of Oregon, 2010).
Sickle cell HbSS phenotype is the most serious form causing pain from vaso-occlusive
crisis and hemolysis, which in turn would be responsible for damage to major organs, life
threatening complications, and mortality (Khoury, Musallam, Mroueh, & Abboud, 2011).
People with sickle cell HbSC, Hb Sβ0 and Hb Sβ+ could present with mild to moderate
symptoms similar to HbSS (Serjeant, 2013).
Pain management, hydroxyurea, and blood transfusions use in SCD have shown
positive effects for decreasing frequency of painful episodes, organ damage, and
increased lifespan (Voskaridou et al., 2010). The problem would be the lack of the
identification of barriers to care, which could result in decreased SCD comorbidities and
increased life span for a greater number of SCD patients. It has been published that
physicians are hesitant to prescribe hydroxyurea and have been found not to be up to date
on sickle cell disease and treatment regimens (Smith et al., 2011; Ware, 2010). In
addition, patients lack education on sickle cell disease, the treatments, and are not
compliant with prescribed medications, such as hydroxyurea (Okam, Shaykevich, Ebert,
Zaslavsky, and Ayanian, 2014). The literature did not identify how geographical location
in the United States affected treatments and mortality of patients with sickle cell disease
creating a gap in the exploration of barriers to care.
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The purpose of this study was to explore the four regions of the United States for
SCD emergency visits, the effect of FDA approval of hydroxyurea for SCD treatment on
the number of emergency visits, and mortality for the years 2006 (16 years later) and
2011 (21 years later). The number of emergency visits phenomenally described a need to
improve the management of SCD; the need for pain management and complications,
provider performance in prescribing hydroxyurea, blood transfusions, and prophylactic
blood transfusions. Patient compliance with hydroxyurea could indicate accessibility, and
complications could be indicative of disease severity and the need for quality health care.
The literature reviews on SCD focused on research in regards to treatment and
mortality variations according to geographical location. Topics reviewed and included in
Chapter 2 were resource utilization, standard and evidence based treatments, morbidity,
and mortality with emphasis on geographical location to assess treatments and outcomes.
The effect of geographical locations examined in North Carolina and California
showed significant factors for high use of emergency services were by adults seeking
pain management, further distance to access care, and holders of government issued
insurance coverage (Hague & Telfair, 2000; Wolfson et al., 2012). Brousseau et al.
(2010) published a retrospective study of eight states representing each region that have
33% of the SCD population in the United States. The study using HCUP data concluded
there were high rates of acute care and return visits for the sickle cell population
(Brousseau et al., 2010). The research did not discuss the effect of geographical location
on treatments, complications, and mortality. Stoles, McKinney, and Silliman (2014)
found that statistical significance for increased incidents of VOC, splenic infarction,
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ACS, and stroke was not reached for children with HbSS more than patients at sea level
locations. The oxygen level and barometric pressure that would be 20% lower than sea
level was not significant for increasing complications (Stoles et al., 2014). Limitations for
the study were the exclusion of additional climate conditions and adults.
Probst, Moore, Glover, and Samuels (2004) reported disparate conditions for rural
locations with a 65% shortage of health care professionals in counties with predominant
ethnic minorities. There was an African American majority in 83% of the counties. The
effect on healthcare would entail a lack of access and a deficit in quality care. Anderson
et al. (2014) argued that deficits in resources for SCD programs has created an
environment of poor quality in healthcare and decreased accessibility. Studies were not
available showing the regional characteristics in the United States for treating SCD with
hydroxyurea as a preventive measure to decrease painful episodes and organ and tissue
damage. In addition, regional mortality rates were not reviewed. The context of the
geographical location studies was rural and urban locations, insurance status, and
accessibility; the treatment standards for SCD by geographical location were not
examined.
Literature Search
Walden University library database was used to search for articles by topic in
health sciences. CINAHL and MEDLINE simultaneous search for using Boolean/ phrase
for sickle cell disease full text. The publication dates entered were 2010 to 2015 for
English language and scholarly (peer-reviewed) journals (839 articles). A Google Scholar
search was done using key word sickle cell disease treatments adults since 2011 (17,800
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results), barriers (8,130 results) and mortality (16,900 results). The majority of the
research studies were conducted in the United States and examined genotypes,
treatments, morbidity and mortality, emergency visits and implications, and hydroxyurea
use. Other areas with studies on SCD included in the review were the United Kingdom,
India, and Africa.
Theoretical Foundation
The Donabedian theory of quality health care (DTQHC) is a conceptual model
proposed by Donabedian (1966) to promote and evaluate quality health care (Kobayashi
et al., 2011) and was used as the framework for this study. The DTQHC model was
conducive in concentrating the focus of the topic to healthcare utilization, treatments, and
outcomes. The last revision of the model was 1987 and included a description for three
dimensions of quality health care; providers of care, recipients of care, and health (Figure
1) (Kobayashi et al., 2011). Sickle cell disease indicators were applied to the dimensions
assigned in the DTQHC model. Ensuring the quality of care for patients with SCD could
decrease comorbidities, improve the quality-of-life, and increase their lifespan.
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Figure 1. Donabedian theory of quality health care for Sickle Cell Disease
The Donabedian model had not been used to assess and evaluate quality of care
and outcomes in sickle cell disease. According to Kobayashi et al. (2011) the model was
applied successfully to assess and evaluate patient perceptions for quality care from
nursing staff during an inpatient hospital admission. Improvements in the quality of
nursing care using the structure, process, and outcomes concepts validated the
effectiveness of the Donabedian approach (Kobayashi et al., 2011). Geographical
location, knowledge and performance of providers, and accessibility of community
resources could affect the health of the population with chronic diseases. Utilization of
the model creates an environment for identifying and evaluating outcomes and effects of
the categorized indicators. The self-care management theory had been used to assess
health outcomes in sickle cell disease and supports intervention to increase resources for
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self-care management while improving health care outcomes (Jenerette & Murdaugh,
2008). The Donabedian model could build upon the self-care management theory with
the inclusion of the assessment and evaluation of provider performance which could
affect resource distribution and self-care management.
Literature Review
The treatments encountered for SCD are symptomatic, preventive, and invasive.
Pain management is needed for unpredictable episodes of VOC (symptomatic);
hydroxyurea, and blood transfusions are preventive measures for acute and preventive
pain management and to decrease organ damage; avoiding overexertion, maintaining
hydration, and extreme temperatures are considered preventive; and surgical
interventions would be invasive. Major organ damage caused by frequent painful VOC
and hemolysis contribute to morbidity and mortality (Platt et al., 1991).
Sickle Cell Disease Manifestations
Sickle cell disease is a genetic inherited blood disorder. Humans have two alleles
at each single autosomal locus; one would be inherited from each parent. In SCD, at the
sickle cell locus there would be the predominant alleles, the A and the S. the genotype
would be any combination of the two alleles (Ballas, S., 2011). Individuals with the AS
genotype have sickle cell trait phenotype and the SS genotype have sickle cell disease
phenotype (Ballas, S., 2011). Sickle cell disease has been challenging to manage because
of the many phenomenal variations. Four genotypes of SCD have been found; HbSS,
HbSC, Hb Sβ0 and Hb Sβ+ (Ballas, S., 2011). In addition, there are three types of pain that
could be experienced at different levels of severity; vaso-occlusive, hemolytic, and
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neuropathic (Niscola et al., 2011). Moreover, each type of pain could be associated with
the type and severity of tissue and organ damage.
Pain and pain management are considered the most prominent manifestation of
SCD and is the number one reason for treatment of SCD patients in the emergency
department (Odesina et al.,2010). Bergman and Diamond (2013) published that painful
crisis was the cause of 60% of patient coming to the hospital for treatment and 90% of
the painful episodes are treated at home. Painful events described would be unpredictable
and severe, causing poor quality of health, excess absences from school and work, and
early death (Neville & Panepinto, 2011). Pain frequency and severity were associated
with causing major organ damage to the spleen, gallbladder, kidneys, brain, male
reproductive organs, and lungs (Platt et al., 1991). Complications of SCD would lead to
surgical removal of the organs, hemodialysis, and treatment with chronic blood
transfusions. Precursors of painful episodes could include hypoxia, dehydration,
overexertion, and exposure to extreme temperatures (Rogovik, Persaud, Friedman, Kirby,
& Goldman, 2011; Smith, Coyne, Smith, & Mercier, 2003).
Overall themes that were prevalent in the literature review of SCD included the
medical implications of pain management, increased use of emergency services because
of ineffective pain management, evidence based preventive treatments with hydroxyurea
to decrease frequent episodes of pain that were not prescribed by physicians and used by
patients, prophylactic use of blood transfusions to offset life-threatening complications,
and mortality. Identified gaps in the literature included geographical location effect on
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health care provider practice and performance standards in treating patients with SCD
using evidence-based methods for pain management, hydroxyurea, and mortality rates.
Emergency Services
Adult sickle cell patients seek emergency care for painful episodes at higher rates
than pediatric and adolescent patients (Tanabe et al., 2010). According to Haywood et al.
(2013) emergency visits for SCD related conditions were over 200,000 annually in the
United States. Vaso-occlusive crisis is the most frequent complaint given for an
emergency department visit; 73% of pediatric patients had episodes of ACS which was
associated with tobacco smoke in the home (Bundy, Strouse, Casella, & Miller, 2011).
Medical and socioeconomic reasons associated with emergency visits found in the study
were asthma, exposure to environmental tobacco smoke, and low income (Bundy et al.,
2011; Glassberg, Wang, Cohen, Richardson, & DeBaun, 2012). The reasons identified
for increased use of emergency services are availability and the services rendered are
accessible for healthcare despite dissatisfaction with the quality of care (Anderson et al.,
2014).
Sickle cell patients seeking emergency care were confronted by stigmas of drug
addiction, resulting in delayed care which could lead to life threatening complications.
Haywood et al. (2013) published that the wait times for SCD patients in emergency
departments was 25% longer than the general patient population rated by race, and 50%
longer than patients with similar pain complaints from long bone fractures. Epstein et al.
(2006) published the health care utilization of 142 sickle cell disease study participants
and concluded that there were 54% emergency visits, 24% office visits, and inpatient
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utilization was 20%. Tanabe et al. (2010) demonstrated the use of emergency services for
adult SCD patients in a prospective, multisite longitudal cohort study; 155 patients with a
median age of 32 years totaled 701 emergency visits over a 10-month period. The studies
reviewed supported that there were increased use of emergency services by SCD patients
for pain management; the phenomenon not investigated were the differences in
emergency service usage based on geographic location.
Emergency service utilization would be considered a priority option for sickle cell
patients due to the complexities and lack of predictability of the disease. The episodes of
painful crisis are sudden and unpredictable. In addition, home pain management regimens
may not be sufficient during a severe episode; the average duration for a painful episode
is 4 to 6 days (Baker & Hafner, 2012). Insufficient pain management and medical care
could lead to increased emergency visits, life-threatening complications, and mortality.
Treatments
The treatments for SCD are based on counteracting the effects of VOC and
hemolysis with pain management; opioids, hydroxyurea, and blood transfusions. Opioids
are used during a painful crisis to decrease the duration of the episodes and improve
quality of life (Baker & Hafner, 2012). Hydroxyurea would be prescribed to increase
fetal hemoglobin levels and thereby decrease the frequency of painful episodes (Baker &
Hafner, 2012). Blood transfusions are given during an acute episode of acute chest
syndrome to dilute the sickling cells with the replacement of normal red blood cells and
would be scheduled prophylactically to prevent future incidents (Bowers, Pepple, & Reid,
2011). For the most part, the use of the recommended treatments for pain management
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and preventive therapy could lead to improvements in the health outcomes of SCD
patients.
Pain Management
The key source for managing SCD effectively is the prevention of frequent
painful incidents to decrease tissue and organ damage, and mortality (Bender and Seibell,
2014). Research has shown that increased episodes of vaso-occlusive crisis causes major
organ damage, increasing incidents of life threatening conditions and the need for various
surgical and medical procedures for sickle cell patients (Booker et al., 2006). A
qualitative study, published by Maxwell, Streetly, and Bevan (1999) gave accounts of
experiences from sickle cell patients for pain management. The findings suggested that
pain management was deficient because of distrust among staff and patients, the
application of stigmas of drug addiction and drug seeking, lack of control on medical
decisions, and failure of staff to provide psychosocial support (Maxwell et al.,1999).
Health care professionals do not believe that the patient has pain, leading to under
treatment. Elander, Marczewska, Amos, Thomas, and Tangayi (2006) and Haywood et al.
(2013) published that poor judgment in making pain management decisions was a
contributory cause to inadequate treatment of pain. Aborting sickle cell pain early after
the onset with hydration, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics,
could lessen tissue and organ damage, and prevent ACS and PHTN (Ballas et al., 2012;
Platt et al., 1991). Baker and Hafner (2012) published that alternatives to opioid treatment
for pain would be the use of parenteral ketorolac (anti-inflammatory agent). The issues
encountered with the use of anti-inflammatory agents are sickle cell pain could be
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refractory and the need for opioids after using ketorolac for effective management would
be delayed increasing the risks for organ damage and mortality (Baker and Hafner, 2012).
Sickle cell pain was found to be poorly mismanaged with under treatment in a
study by (Elander et al., 2011; Niscola et al., 2009). Recommendations have been made
for the development of care plans and standardized treatments for SCD pain management
to offset mismanagement of SCD pain. Ballas et al. (2012) published that the
management of sickle cell painful crisis could decrease inflammation that would
normally increase with recurrent episodes, decrease incidents of organ damage and
serious complications, such as ACS, PHTN, and decrease incidents of sudden death.
Barriers to treatments using evidence-based pain management protocols have a
negative influence on the benefits for prescribing opioids, hydroxyurea, and the use of
blood transfusions. Patients with painful sickle cell crisis should be treated aggressively
with several methods to counteract symptoms and complications (Odesina et al., 2010).
Healthcare providers should not treat SCD symptoms by means of the traditional generic
methods; sickle cell treatments should be based on the pathophysiology of the disease
process (Mousa et al., 2010). Frequent episodes of VOC were associated with mortality
as demonstrated in a cohort study of adults with SCD (Darbari et al., 2013). Odesina et
al. (2010) demonstrated that several therapies were needed for effective pain management
in SCD. The results of the study were evident after the medical records were reviewed
and showed a high use of treatment with one medication, delays in the medical
examination, and delayed times for treatment with analgesics (Odesina et al., 2010). A
cross-sectional survey published by Thompson and Eriator (2014) reported that 92% of
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adults with SCD experienced pain with a duration of more than 6 months and 91% used
alternative therapies for pain control. Adults with SCD received low quality healthcare
because the use of evidence-based treatments was not provided (Odesina et al., 2010). It
was published by Cain, Vang, Simone, Hebbel, and Gupta (2011) using mouse models
that sickle cell deep tissue pain and cold sensitivity was increased with age and hypoxia;
which could be associated with SCD adults increased use of emergency services for pain
management.
Opioids. Patients with SCD require large and frequent dosages of narcotic
analgesics. Severe pain in SCD is treated with opioids and decisions for the type of drug
and dosage should be individualized (Niscola et al., 2009). According to Delicou and
Maragkos (2013) and Mousa et al. (2010) the standard treatment for severe pain in SCD
was morphine. Glassberg et al. (2013) published the results of a cross-sectional survey
which showed that the majority of emergency physicians self-reported adherence to the
pain management standards for SCD; opioids (90%) and repeating the dose in 30 minutes
for ineffective management (85%). Physicians with a negative attitude about SCD were
less likely to repeat the medication in 30 minutes (20%) (Glassberg et al., 2013).
Barriers to effective opioid use include healthcare provider hesitancy to prescribe
dosage amounts needed to manage pain and did not trust that the patient was honest about
the level of pain (Elander et al., 2011). Stigmas for drug addict and malingerer have been
attached to patients with chronic nonmalignant pain that require opioids for control
(Glassberg et al., 2013). According to Vallerand and Nowak (2010) barriers to opioid
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therapy exists within the healthcare system and society limiting the ability of the
individuals to access and maintenance of adequate pain management.
Hydroxyurea. Research on the use of hydroxyurea has shown that the drug is
safe, effective for decreasing painful episodes, and decreases organ damage and
premature mortality in SCD (Voskaridou et al., 2010). Yet, a problem exists in not using
the drug as a standard treatment for SCD. Preventive treatments used for sickle cell to
decrease VOC and prevent complications from organ damage, and early mortality include
hydroxyurea and blood transfusions (Voskaridou et al., 2010). The use of hydroxyurea as
a treatment for SCD has been explored for greater than 25 years for safety and affect
(Ware, 2010). It is the only treatment for SCD approved by the FDA.
Hydroxyurea was first used as a treatment for SCD in 1984; it was found to
decrease episodes of VOC and increase Fetal Hemoglobin (HbF) which is decreased in
SCD patients and replaced with the mutant gene HbS (McGann & Ware, 2011). In
addition, SCD patients are advised to remain well hydrated (drinking fluids) and avoid
extreme weather conditions (hot, cold, and windy) (Smith et al., 2003). Hydroxyurea and
blood transfusions are considered preventive medical treatments for adults with SCD to
improve health and health outcomes. In any case, barriers for using hydroxyurea and
blood transfusions could occur from misinformation and lack of knowledge.
Physician and patient hesitancy to comply with the use of hydroxyurea could
arise from the controversial use for SCD since the original use of the drug was antineoplastic and the long-term safety effect was not known (Ballas et al., 2013). According
to Ware (2010), the use of hydroxyurea in young patients with SCD would be considered
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safe; however, reports of cancer development in patients taking hydroxyurea for SCD
have been reported. The problem with hydroxyurea would be that 59.5% of SCD patients
self-reported never using the drug, former use was self-reported by 65.2 %, and current
use was 52.9 % (Haywood et al., 2011). The question would be; does geographical
location matter for increasing or decreasing the use of hydroxyurea? The reasons for
hydroxyurea lack of use were feeling different after taking the medication, advised by the
physician, and changes in conditions were not noted (Haywood et al., 2011; Ware, 2010).
Medically and clinically the benefits for taking hydroxyurea for SCD would
outweigh the risks; such as reduction of white blood count, lower bilirubin levels, and
less hemolysis (Ballas, Singh, Adamas-Graves, & Wordell, 2013; Smith et al., 2011;
Ware, 2010). Smith et al. (2011) published that hydroxyurea was significant in
decreasing painful episodes, analgesic use, and visits to healthcare facilities. According to
McGann and Ware (2011) the benefits and effectiveness of hydroxyurea treatment has
been explored for the last 25 years and should be considered a standard treatment for
sickle cell disease. Voskaridou et al. (2010) found that the use of hydroxyurea could
decrease episodes of VOC and hemolysis which in turn decrease damage to major organs
and mortality rates. In addition to ensuring appropriate treatment availability for SCD,
dissemination of information, and education for patients and physicians would be
beneficial.
Blood transfusions. Blood transfusions are used for acute and chronic
prophylactic treatment for the prevention and treatment of ACS, PHTN (Miller &
Gladwin, 2012), stroke (Powers, Chan, Hiti, Ramilone, & Johnson, 2005), splenic
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infarction (Owusu-Ofori & Hirst, 2013), and priapism ((Azik et al., 2012) and should be
considered a standard treatment. The normal red blood cells are used to dilute the
concentration of sickled cells to decrease organ damage and mortality (Owusu-Ofori &
Hirst, 2013). Research has shown that blood transfusion should be used in the event of
severe crisis episodes specifically when there is a previous history of ACS and PH
(Miller & Gladwin, 2012).
Most deaths from SCD occur in the hospital during an acute painful crisis; lifesaving treatments during these episodes would be blood transfusions (Allareddy et al.,
2014). Emergency management for severe SCD painful crisis would use blood
transfusions to decrease incidents of premature mortality caused by anemia,
vasculopathy, and organ damage (Vichinsky et al., 2011). Patient safety should be
considered by health care providers by obtaining a detailed history on SCD patients to
avoid blood transfusion complications and to make informed medical decisions for
treatment.
Like other treatments, the use of chronic blood transfusions could cause
complications, alloimmunization, and iron overload (Cho & Hambleton, 2014).
Alloimmunization occurs when the body develops antibodies against the transfused
blood, making it difficult to provide a compatible blood match for future transfusions
(Cho & Hambleton, 2014). Cho and Hambleton (2014) published that the benefits of
regular blood transfusions have been associated with improving outcomes and could have
several common side effects.
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Transfusion reactions, iron overload, transfusion transmitted infections, and
alloimmunization have been associated with regular blood transfusions (Detterich et al.,
2013). Sickle cell patients normally have a lower hemoglobin and hematocrit level than
the population without SCD and sickle cell trait (Koren, Fink, Admoni, TennenbaumRakover, and Levin, 2009). Koren et al. (2009) published that the management of the
hemoglobin and hematocrit levels in SCD patients would involve determining the
optimal levels for viscosity and oxygen carrying capacity, instead of attempting to
maintain the medical textbook levels; female values equal 12 to 14 (hemoglobin) and 34
to 36 (hematocrit) and 14 to 16 (hemoglobin) and 36 to 40 (hematocrit) for males. Sickle
cell patients would have hemoglobin values of (±4 to 6) and hematocrits (±10) points
lower. Bowers et al. 2011 found that with the determination of the optimal hematocrit for
sickle cell patients, oxygen transport could be maximized, viscosity dependent VOC
could be reduced, and transfusion regimens could be appropriately assessed.
Sickle cell disease patients should be involved with treatment regimens and have
an awareness of test results, dates of testing, and optimal levels for individual
hemoglobin and hematocrit tests to avoid transfusion complications. For this study, blood
transfusions in the emergency setting would denote compliance with standard treatment
regimens for patients presenting with ACS, PH, splenic infarction, priapism, and stroke.
Above all, the literature reiterated the importance of the knowledge necessary to treat
sickle cell complications effectively without creating exacerbations.
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Morbidity
Symptoms related to morbid conditions increase during painful episodes and
presenting complaints to the emergency department could originate from organ and
vesicular damage (Glassberg et al., 2012). The common major organ damage in adults
from frequent painful episodes would include lung damage (ACS and PHTN), brain
infarcts (stroke), and kidney injury (Platt et al., 1994). In this section, a brief description
is provided for the morbidities. The symptoms of chest syndrome could include fever,
coughing, chest pain, and diagnostically a chest x-ray showing a pulmonary infiltrate
(Miller & Gladwin, 2012). Acute chest syndrome in adults with SCD could be manifested
from fat embolization in the bone marrow during a painful crisis, which could result in
pulmonary emboli causing symptoms of dyspnea and chest pain, with hypoxia (Khoury et
al., 2011). Paul, Castro, Aggarwal, and O’Neal (2011) published that acute chest
syndrome was considered the most common reason for hospital admission related to
symptoms and clinical findings, and death because of misdiagnosis. Pulmonary
hypertension has been associated with hemolysis and hemolytic anemia. According to
Miller and Gladwin (2012) PHTN occurrence is increased in adults because of chronic
anemia, intravascular hemolysis, and increased cardiac output derived from systemic
vascular and pulmonary damage.
Wang et al. (2013) published that stroke occurs in 24% of sickle cell patients by
the age of 45 years. The high incidence of stroke in adults with SCD and is associated
with cerebral perfusion relationship to the degree of anemia (Prohovnik, Hurlet-Jensen,
Adams, Devivo, & Pavlakis, 2009). The initiation of blood transfusions as a treatment
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regimen could be beneficial in maintaining optimal individual hemoglobin level and
stroke prevention (Detterich et al., 2013). Neurological symptoms such as slurred speech,
severe headache, and visual disturbances could be reasons for seeking emergency
treatment.
Kidney injury in sickle cell disease could result in dialysis dependent kidney
failure also known as end-stage renal disease, and death (Audard et al., 2014). Audard et
al. (2014) published that ischemic injury to kidneys in sickle cell disease was a common
occurrence during VOC. Treatments used to counteract the effects of VOC activity would
include monitoring of intravenous hydration to correct electrolyte imbalances (Audard et
al., 2014).
Providers of care to sickle SCD patients ought to be aware that medications used
to treat painful episodes and blood transfusions could be the primary source of a
complication. Health care providers must obtain a detailed history on SCD patients to
avoid pain management and blood transfusion complications and to make informed
medical decisions for treatment. The literature reviewed did not explore whether
morbidity patterns vary based on geographical location and regionally.
Mortality
Mortality rates for adult SCD patients increased during a study conducted from
1979 to 2005; it was published that few children with SCD lived to adulthood and the
median age of death was 48 years for females and 42 years for males (Platt et al., 1994).
Bender and Seibell (2014) published that a subset of SCD patients would live to ages
greater than 55 years, although high rates of morbidity would persist. Contributing to the
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increased lifespan would be decreased mortality rates in children by 3% and improved
treatments (Bendell & Seibel, 2014). An analysis of the geographic location for
treatments and mortality rates could provide information on the subset of SCD that have
increased lifespans over 55 years. In addition, increased morbidities have been associated
with premature mortality.
Research has shown that deaths in SCD occur within three days of admission to
the hospital with a diagnosis of SCD painful crisis (Allareddy et al., 2014). Given that
treatment and organ damage complications could be associated with adult SCD mortality.
Manifestations of lung damage was the origin of the two most common causes of death in
adults with SCD HbSS from frequent VOC and hemolysis, namely acute chest syndrome
and pulmonary hypertension (Bender & Seibell, 2014).
Summary
The research for SCD has focused on treatments, the effects of treatments,
complications, and mortality. Research was lacking on how barriers to care could affect
health outcomes, quality of life, and mortality for adults with SCD. Lack of accessibility
to care, stigmas, and lack of knowledge for treatments could contribute to the barriers. In
efforts to close the gap and promote effective evidence-based treatments for SCD, the
World Health Organization (WHO) developed standards of care to be used as guidelines
for SCD pain management (Moussavou et al., 2004). The study followed WHO standards
and guidelines for pain management, and pain relief was experienced by 81.6% of the
patients (Moussavou, et al., 2004). Additional pain management guidelines and protocols
have been published for SCD to ensure quality care (Rees et al., 2003; and Ballas, Carlos,
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& Dampier, n.d.). The standards of care could designate priorities in the management of
SCD complications and serve as a catalyst in improving the quality of life (Yale, Nagib,
& Guthrie, 2000).
According to Bhagat, Baviskar, Mudey, and Goyal (2014) sickle cell patients
reported a significantly lower health related quality of life when compared to chronically
ill patients of non-communicable diseases. Sickle cell patients have beliefs that the
disease could be better managed and accessibility to quality care and appropriate
treatments could improve health outcomes and quality of life (Bhagat et al., 2014). Sickle
Cell education could improve the prescribing of treatment regimens (physicians), and
compliance with treatments (patients). Several studies (Pack-Mabien & Haynes, 2009;
Yale et al., 2000) argued that a multidisciplinary approach should be used to manage the
care of SCD patients to increase the quality of care and improve health outcomes. The
multidisciplinary healthcare team would include a SCD specialist, registered nurse, social
worker, patient, and family. Yawn et al. (2014) published strong, moderate, weak, and
consensus recommended standards of care for adults with SCD morbidities of VOC,
ACS, stroke, renal failure, and PHTN. The strong recommendations are listed below with
the consensus recommendations listed for acute renal failure (Yawn et al., 2014).
•

VOC: rapid treatment with opioids (intravenous route) for severe pain;

•

VOC/ ACS: use of incentive spirometer to prevent ACS during acute VOC;

•

ACS/ Stroke: blood transfusions would be used for severe episodes and
consultation with a SCD expert;

•

ACS: intravenous cephalosporin, oxygen, and oral macrolide antibiotic;
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•

Stroke: chronic transfusion therapy program;

•

Acute Renal Failure (consensus): monitor renal function daily (creatinine levels
and fluid intake and output), blood transfusions are not recommended, use
hemodialysis when needed for exacerbated conditions; and

•

PHTN: obtain a diagnostic echocardiogram.

Despite the efforts to promote quality care, only 59% of SCD have shown improvements
in health outcomes and decreased mortality (McGann & Ware, 2011). An analysis on
treatments, morbidity, and mortality according to geographical location could reveal
additional barriers and deficits in care.
Given the variations in treatment regimens, health, and health outcomes for
patients with SCD, the effect of regional contribution was evaluated in this study. The
methods that were used to evaluate the association of geographical location with
emergency department usage, treatments, and mortality of adults with SCD in the United
States are described in Chapter 3.
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Chapter 3: Research Method
Introduction
The purpose of the study was to examine the impact of geographical location on
the health outcomes of patients with SCD in regards to accessibility to care, treatments,
and mortality. Accessibility to care and physician performance for treatment regimens for
chronic diseases could vary by geographical location. Several studies (Davis et al., 1997;
Smith et al., 2011) have shown barriers affecting the health outcomes of SCD patients
include decreased healthcare accessibility and knowledge deficits for the use of
hydroxyurea for treatment by providers and patients. Deductively, the literature reviewed
reflects that the negative effects of barriers to care in SCD could cause increased
comorbidities, decreased quality-of-life, and decreased life span.
Chapter 3 outlines the design of the study. The sections in the chapter discuss the
targeted population, research design, sampling and sampling procedures, and methods
that were used to analyze the data. The reliability and validity evidence HCUP datasets,
which is sponsored by the AHRQ, was provided along with evidence that the data was
sufficient to respond to the research questions.
Research Design and Rationale
Dependent Variable(s)
The dependent variables used for this quantitative research design included
emergency visits and mortality rates 16 and 21 years after FDA approval of hydroxyurea
for SCD treatment. Emergency visits for the purpose of this study indicated accessibility
to care, disease management, and severity of disease. Hydroxyurea treatment is the only
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drug approved by the FDA to treat SCD; in this study16 and 21 years after the approval,
emergency visits and mortality rates were compared regionally and the results were
considered an indicator of hydroxyurea use for disease management, severity of disease,
and the need for accessible health care. Mortality rates were noted from inpatient hospital
admission deaths with ICD-9 CM Codes 282.60 (SCD nonspecific), 282.61 (SCD
without crisis), and 282.62 (SCD with crisis) listed in the medical record within the first 5
diagnoses (Diagnosis 1, Diagnosis 2, Diagnosis 3, Diagnosis 4, or Diagnosis 5).
Independent Variable(s)
The four regions in the United States were considered the geographic location and
the independent variable. An examination of the Northeast, Midwest, South, and West
regions was conducted to analyze significant associations in the medical care and health
outcomes of sickle cell patients.
Covariable(s)
Sickle cell HbSS is dominant in subSaharan African descendants, therefore the
population in the United States included were African Americans synonymous with the
race listed as Black reported in the NIS datasets; NEDS did not include race as a variable.
Covariables that could affect the outcome of the dependent variables were insurance
status, income level, age, and gender. Age encompassed adults ages 21 years and older.
Gender of male and female along with income level, and insurance status were used to
provide a demographic description of the population.
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Research Design
Correlational research. A retrospective correlational research design was used to
examine the relationship of how living in different regions could affect the health and
outcomes for adults with SCD. State data reported to NIS 2006 and NIS 2011 that was
used in the study include race, gender, age in years, ICD-9-CM Codes 282.60, 282.61,
and 282.62 diagnoses (1 through 5), in-hospital deaths, region of hospital, income level,
and type of insurance.
Emergency department visits and national estimates were tracked using NEDS.
The elements that were reported by the 46 states to the NEDS 2006 and NEDS 2011
database that were used in the study are age in years, gender, ICD-9-CM Codes 282.60,
282.61, and 282.62, region of hospital, type of insurance, income level, and emergency
department visits and dispositions (deaths) of patients. Researchers using the database are
allowed to study procedures and conditions related to emergency service use. The
independent variable (regions) and two dependent variables (ED visits and mortality)
were analyzed for correlations with a Confidence Interval of 95% and level of
significance of (0.05).
The correlational study design was used to suggest possible associations between
the independent and dependent variables. The type of association and the existence of
extreme scores were demonstrated using bar charts to present visual representation. There
were three dependent variables and one independent variable that was analyzed to
determine if a significant relationship existed to contribute knowledge on how the health
care system and health outcomes for sickle cell patients could be affected by regional
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location. The secondary data provided an overview of SCD patients in the four regions of
the United States for the years 2006 and 2011. The sampling method did not allow for the
use of the cross-sectional design. Prevalence of chronic diseases is assessed from data
collected from a defined period of time using a cross-sectional design to provide
information on the entire population in the study. Sampling of the SCD population with a
specific phenotype, SCD HbSS, was examined for regional differences; comparisons
were not made between the population without SCD and the SCD population.
Longitudinal research designs are used to compare the effects of diseases over periods of
time. For example, SCD data would be used for the years of 2009, 2010, 2011 2012, and
2013 to compare changes in the health outcomes during the time periods analyzed. The
data from two time periods was used for this study which is appropriate for a
correlational design.
Represented in the datasets for NIS 2006, NIS 2011, NEDS 2006, and NEDS
2011 was information collected from hospitals in 46 of the HCUP partner states and
representative of the Northeast, Midwest, South, and West regions (Agency for
Healthcare Research and Quality, 2012). The number of emergency visits was an
indicator for accessibility to quality care, appropriate disease management with
prescribed medications for home use, and health care quality would be denoted by
decreases or increases in mortality rates across the United States among patients with
SCD. Emergency visits have been shown to increase among adults with SCD, while there
is a low incidence of hydroxyurea use, and the lifespan is short (Andemariam et al.,
2014). The correlational research design was used to establish the type of association
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between the variables, denote changes in scores, determine whether the relationship is
negative or positive, and determine the strength of the relationship.
Healthcare Costs and Utilization Project
The HCUP has a collection of databases with 46 participating states; the two
databases that were used for this study are the NIS 2006, NIS 2011, NEDS 2006, and
NEDS 2011 which included 46 states that contributed information to both databases for
the years 2006 and 2011. The NIS database contains data on inpatient hospital
admissions, dispositions, insurance status, and length of stay (NIS 2006 and NIS 2011).
The NEDS has emergency department data which includes the reason for visit, diagnoses,
and discharge disposition (NEDS 2006 and NEDS 2011). The use of NIS data estimates
over 36 million weighted inpatient admissions, treatments, and discharge dispositions
annually (Agency for Healthcare Research and Quality, 2013). A representation of
special patient populations, a large sample size, uncommon treatments, and rare
conditions are found in NIS and NEDS. The data was used to explore the relationship of
geographical location to the number of emergency visits by sickle cell patients and
mortality rates. The knowledge gained could influence the allocation of resources and
dissemination of evidence-based knowledge for SCD which could reduce emergency
services usage, improve health outcomes, and reduce health care expenditures.
Methodology
Target Population
The target population included adults (21 years and older), males and females
with SCD HbSS identified by ICD-9-CM Codes 282.60, 282.61, and 282.62, with a
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hospital registration and discharge as an inpatient or emergency department patient. The
targeted population varied by year and by the dataset with NIS representing the frequency
of inpatient admits and NEDS representing the frequency of ED visits; NIS 2006
(N=67,214), NIS 2011 (N=80,040), NEDS 2006 (N=164,698) and NEDS 2011
(N=215,296). Regionally, frequencies for inpatient admissions and ED visits for the
targeted population was NIS 2006; Northeast (N=17,657), Midwest (N=13,242), South
(N=30,799) West (N=5,517), NIS 2011; Northeast (N=13,829), Midwest (N=13,663),
South (N=36,651) West (N=6,538), NEDS 2006; Northeast (N=25,300), Midwest
(N=23,190), South (N=98,984) West (N=17,230), NEDS 2011; Northeast (N=43,447),
Midwest (N=25,602), South (N=122,695) West (N=13,552). The regions were
represented by the states of Alaska, Arkansas, Arizona, California, Colorado,
Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Missouri,
Nebraska, Nevada, New Hampshire, New Jersey, New York, New Mexico, North
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South
Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, and
West Virginia, Wisconsin, and Wyoming. The number of states that contributed data to
HCUP NIS and NEDS for the years 2006 and 2011 varied: NEDS 2006 (24), NEDS 2011
(30), NIS 2006 (38) and NIS 2011 (46) (Figure 2, Figure 3, Figure 4, and Figure 5).
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Figure 2. States by region for NEDS 2006
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Figure 3. States by region for NEDS 2011
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Figure 4. States by region for NIS 2006

49

Figure 5. States by region for NIS 2011
Sampling and Sampling Procedures
A 20% sample of all United States community hospitals is approximated in the
NIS and NEDS databases. Data for the NIS 2006 files was produced from 1,045 sampled
hospitals (Agency for Healthcare Research and Quality, 2012). Included in the sample
were hospitals in the Northeast (137), Midwest (299), South (415) and West (194). There
were 1,049 hospitals in the stratified sample of NIS 2011 data containing discharge
records. National estimates for dispositions would use the NIS 10% subsample core file
to weight the data for the years 2006 and 2011 and statistical analysis. The number of
sampled hospitals for the NIS 2011 data by region includes the Northeast (129), Midwest
(306), South, (417), and West (197). The NEDS 2006 data was comprised of 955
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hospital-based emergency departments with over 120 million weighted admits to the ED
(Agency for Healthcare Research and Quality, 2012. There were 951 sampled hospital
based emergency departments sampled for the NEDS 2011 database and over 131 million
weighted ED admits. The NEDS data represents 67% of the United States population
(Agency for Healthcare Research and Quality, 2012).
The AHRQ used stratified random sampling, a probability sampling technique, to
collect data for HCUP; the samples of sickle cell data are reflective of subgroups that are
homogenous, do not overlap, the population is exclusive, and large sample sizes can be
accommodated (Frankfort-Nachmias & Nachmias, 2008). The sample was stratified by
region (Northeast, Midwest, South, and West), hospital ownership (profit, not-for-profit,
public, private, government), location (rural and urban), and hospital type (teaching,
nonteaching, trauma center. Simple random sampling was not chosen because of the large
sample size. Systematic sampling would not allow the opportunity of equal selection of
the population. Cluster sampling requires two stages, a sample would be selected of the
area and a sample would be selected for the population and a true representation of the
population would not be met (Frankfort-Nachmias & Nachmias, 2008).
Inclusion criteria. The inclusion parameters consisted of adults in the age group
of 21 years and over with SCD HbSS from NIS 2006, NIS 2011, NEDS 2006, and NEDS
2011 datasets from the 46 states participating in HCUP for the years 2006 and 2011.
First, the ICD-9-CM Codes 282 .60 (nonspecific SCD), 282.61 (SCD with crisis), and
282.62 (SCD HbSS without crisis) were selected; next descriptive statistics followed to
designate the frequencies for race (NIS 2006, 2011), age of 21 years and older, income
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level, insurance status, ED visits and dispositions (deaths), inpatient admissions and
deaths, and regions (Northeast, Midwest, South, and West).
Exclusion criteria. Excluded from the data were patients in age groups less than
21 years, patients that did not have ICD-9 Code 282.60, 282.61, or 282.62 listed in the
first five diagnoses in the medical record, and states that did not report data to NIS 2006,
NEDS 2006, NIS 2011, and NEDS 2011. After the inclusion criteria were met for the
sample, the population was categorized into the corresponding regions (Northeast,
Midwest, South, and West).
Power Analysis
Chi-Square was used to analyze the sample because the sample size was large,
and the population in the sample had a diagnosis of SCD. For NIS datasets the patients
that died while in the hospital were tallied and NEDS datasets were used for frequency of
ED visits. The frequency data was used for the analysis. Cramer’s V analysis was used to
determine the effect size NIS 2006 (.016), NIS 2011(.016), NEDS 2006 (.104), and
NEDS 2011 (.010). Effect size was recorded as small in all four datasets which could
occur with large sample sizes (Faul et al., 2009).
Procedures for Recruitment, Participation, and Data Collection
The AHRQ invites all hospitals located in the 50 states of the United States to
participate in HCUP since 1988, and 46 states signed up as partners to participate in
HCUP (Agency for Healthcare Research and Quality, 2012). The number of HCUP
partner states that provide annual health care data include inpatient (46), same day
surgery and services (34), and emergency services (32) (Agency for Healthcare Research
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and Quality, 2012). Reporting of the data is voluntary and annual compliance with
reporting to the databases is not consistent for all states. The choice of databases for state
reports include the NIS, NEDS, Kids’ Inpatient Database (KID), State Inpatient
Databases (SID), State Ambulatory Surgery and Services Database (SASD), and State
Emergency Department Databases (SEDD) (Agency for Healthcare Research and
Quality, 2012).
Forty-six states entered data for NIS 2006, NIS 2011, NEDS 2006, and NEDS
2011(Agency for Healthcare Research and Quality, 2012). The NIS is sampled from the
SID and approximates 20% of discharges from community hospitals from the data of
more than 7 million hospitals annually (Agency for Healthcare Research and Quality,
2012). National trends for health care utilization, quality, outcomes, and access are
analyzed, tracked, and identified by policymakers and researchers using NIS data
(Agency for Healthcare Research and Quality, 2012).
In the NIS 2006, NEDS 2006, NIS 2011, and NEDS 2011 data was collected from
46 states that are representative of the four regions of the United States (Northeast,
Midwest, South, and West) (Agency for Healthcare Research and Quality, 2012). The
number of emergency visits was used as an indicator for accessibility and disease
management. Health outcomes were determined by mortality rates. Comparisons were
made regionally with the inclusion of mortality rates across the United States among
patients with SCD. I used a correlational research design was to establish the association
between the variables, denote changes in scores, determine whether the relationship was
negative or positive, and determine the strength of the relationship.
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Procedure for Gaining Access to Dataset
HCUP data is sponsored by the AHRQ for the purpose of research to assist with
public policy, improving health care quality, and as a resource to states and the federal
government in making decisions on program development and funding (Agency for
Healthcare Research and Quality, 2012). An application requesting the data was filed
after completing an online tutorial on data usage and the International Review Board
(IRB) approval. The IRB approval number assigned was 01-04-16-0351894. Permission
was granted to use the data following the guidelines for confidentiality and protection of
identities for individuals and establishments as outlined by the Health Insurance and
Affordability Act of 1996 (HIPAA). The application process involved inclusion of the
type and purpose of the research, how the data would be used, and the name and reason
additional persons would have access to the information. The procedure for accessing the
data required the completion of an online tutorial, filing an application and signing the
agreement, and payment of fees to purchase the data.
Reputability of the Sources
The NIS datasets for the years 2004 to 2010 were used in a retrospective analysis
by Allareddy et al. (2014) to examine acute chest syndrome as a predictor of mortality in
adults with SCD. A regression model analysis adjusted the effects of the independent
variables which included sex, race, age, type of sickle cell crisis and admission,
comorbidities, hospital characteristics, and insurance status. Sickle cell disease HbSS was
found to be the phenotype for 84.3% of the admissions (Allareddy et al., 2014). The need
for mechanical ventilation and acute chest syndrome predicted higher mortality rates.
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Okam et al. (2014) published that following the approval of hydroxyurea for use
in SCD by the Food and Drug Administration (FDA) in 1998 there was not a constant
decline in hospital admissions using confidence interval of 95%. The study used HCUP
datasets for NIS 1998 to 2008 in a retrospective cohort study to test the hypothesis that
hospitalizations would decrease with the availability of hydroxyurea.
An examination by Roghmann et al. (2013) on the likelihood of hospitalization
contributory factors for priapism diagnoses used the HCUP NEDS data from 2006 to
2009. A prediction of hospital admissions was made based on comorbidities, emergency
department volume, insurance status, and hospital location. The results showed SCD
patients (OR 2.22, p <0.001); significant for hospital admission and seeking emergency
treatment for priapism.
Stein, Flum, Cashy, Zhao, and McVary (2013) published study results using
HCUP data from NEDS 2006 to 2009 datasets which examined encounters for priapism
visits, associated diagnoses by ICD-9-CM codes, hospital characteristics, and hospital
charges. The nationwide estimates were calculated with the established weighting of the
sample and 21% of the patients had a diagnosis of SCD.
Operationalization of the Variables
The HCUP NIS 2006, NIS 2011, NEDS 2006, and NEDS 2011 datasets were
constructed from administrative data reported for billing from participating community
hospitals. The information collection process begins with the initial admission to the
hospital as an in-patient or emergency department visits and contains ICD-9-CM codes,
Current Procedure Terminology (CPT) codes, Clinical Modification (CM) coding for
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comorbidities, and disposition. Data collection for NIS 2006 and NIS 2011, NEDS 2006,
and NEDS 2011 occurred 16 and 21 years after the approval of hydroxyurea and was
used to compare the number of emergency visits and mortality rates.
For this study, a data file was created from NIS 2006 and NIS 2011 datasets for
inpatient admission records and deaths of patients with the diagnoses codes 282.60,
282.61, and 282.62 listed within the first five diagnoses, regions, 21 years and older,
income level, gender, and insurance status. Data files were created from NEDS 2006 and
NEDS 2011 datasets for emergency visits and ED dispositions with data that included
diagnoses codes 282.60, 282.61, and 282.62 listed within the first five diagnoses, regions,
21 years and older, income level, gender, and insurance status. Hospital location (region)
identifiers were used to designate geographical location and ascertain regional location.
There were not any outliers identified in the data. The main predictor variables for the
study were regional location (Northeast, Midwest, South, and West); the outcomes
included the number of emergency visits and mortality rates for the years 2006 and 2011.
Covariates that could affect the outcomes existed with age, gender, insurance status, and
income level and were explored using descriptive statistics to assess variations and
regional differences (Table 1).
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Table 1.
Variables, Operational Definitions, and Conceptualizations
NIS
2006
2011
X

NEDS
2006
2011
X

X

X

DV

X

IV

Covariate

Variable Name

Operational
Definition

X

AGE

Age listed in numbers;
0 to 124 years
(1) 21 years’ plus

Age in years

Level
Of
Measurement
continuous

X

FEMALE

Gender:
(0) male,
(1) female
Uniform coding is
used for race:
(1) white
(2) black
(3) Hispanic
(4) Asian or Pacific
Islander
(5) Native American
(6) Other
Household income
2006:
(1) $1-$35,999
(2) $36,000-$44,999
(3) $45,000-$58,999
(4) $59,000+
Household Income
(2011)
(1) $1-$38,999
(2) $39,000-$47,999
(3) $48,000-$62,999
(4) $63,000+
Information for
expected primary
payer:
(1) Medicare
(2) Medicaid
(3) Private including
HMO
(4) Self pay
(5) No charge
(6) other
Region of the hospital:
(1) Northeast
(2) Midwest
(3) South
(4) West
Diagnoses by ICD-9CM Codes
(1) 282.60
(2) 282.61
(3) 282.62
(0) did not die
(1) died
Emergency
Department events
(0) ED admission (did
not die)
(1) Died in ED

Gender

dichotomous

Race

categorical

Household income
by zip code

categorical

Insurance Status

categorical

Regional location
of the hospital

categorical

Diagnoses by
ICD-9-CM Codes
282.60, 282.61,
282.62

nominal

Inpatient hospital
deaths
Emergency
Department visits
and deaths

categorical

X

RACE

X

X

X

ZIPINC_QRTL

X

X

X

PAY1

X

X

X

HOSP_REGION

X

X

X

X

DX1
DX2
DX3
DX4
DX5
DIED

X

ED_EVENT

X
X

Conceptual
definition

categorical
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The number of emergency visits could be an indicator for accessibility to health care,
disease management was recognized with emergency visits, and health outcomes were
acknowledged with mortality.
Data Analysis Plan
Standard quality control procedures exercised by HCUP for age and date of birth,
admission, discharge, and ICD-9-CM codes include confirmation that the data is valid,
consistent internally, and when feasible consistent with norms (Agency for Healthcare
Research and Quality, 2012). Inconsistent and questionable values are labeled with C or
negative 6-filled. The inconsistent values are not changed or fixed; special missing values
labels are assigned to preserve the anomalies for the researcher to investigate (Agency for
Healthcare Research and Quality, 2012). Edit failures are tabulated and used to assess the
quality for each data source. Quality review is conducted by an independent contractor
annually to verify all numerical and categorical data elements, frequency distributions,
and cross-frequencies (Agency for Healthcare Research and Quality, 2012). Procedures
for automated quality control are used to assess the validity of values; numeric data
verified as numeric, ranges checked against norms, maximum allowed values checked
against data ranges, and diagnostic and procedure codes verified against norms (Agency
for Healthcare Research and Quality, 2012). Internal consistency is assessed to capture
inconsistencies, such as birthdates that would be inconsistent with the documented age.
Edit checks are performed on HCUP data annually since 1998; the edit check numbers
are assigned with a description and the action taken (Agency for Healthcare Research and
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Quality, 2012). Missing values were eliminated in this study because the variables that
were selected from the dataset had less than five percent missing values.
Data Cleaning Procedures
Statistical Program for Social Sciences (SPSS), Stata Data Analysis and Statistical
Software for Professionals, and Statistical Analysis Software (SAS) are compatible with
HCUP datasets; SPSS was used in this study for statistical analysis. The data was
provided on CD-ROMs, downloaded, unzipped, and saved in folders on the (C) drive of
the PC. The HCUP datasets were downloaded to SPSS using the SPSS load files that
were provided by HCUP.
The data was converted to SPSS, reviewed, and cleaned in stages. First the
variables were examined and there were not any errors detected. Next values were added
to the variables according to the HCUP values that were assigned in the codebook. Then,
frequencies were checked and compared to the summary statistics provided on the
H.CUPnet web page to ensure the datasets were downloaded correctly, the statistics were
accurate, and to ensure the reliability and validity of the research (Field, 2013). The data
was screened for missing data, blank entries, typing errors, coding errors, and misfiled
data elements.
The data was cleaned so the same results could be obtained when applied to a
similar situation. In addition, valid data would measure the concepts intended. The last
step was the selection and coding of the variables that would be used for this study.
Variables that were recoded were age by birthdate 0-124 years (21 years plus) and the
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first five diagnoses (DX primary, DX1, DX2, DX 3, DX4) were auto recoded using SPSS
for ICD-9-CM Codes 282.60, 282.61, and 282.62.
Research Questions and Hypotheses
I used descriptive statistics and frequencies to define the targeted SCD population
in the areas of insurance status, income level, age, and gender. Regression was not used
for statistical analysis because the assumptions for homoscedasticity were not met and the
results would be biased. Chi-Square analysis was used to assess if there was a significant
association between the effect of regions on insurance status, age, gender, income level,
emergency visits, and mortality (dependent variables) and regions (independent) variable.
The research questions that were explored in the present study using HCUP data from
NIS 2006, NIS 2011, NEDS 2006, and NEDS 2011 include
RQ1: Is there a significant association between emergency services use
(accessibility) among adults with SCD and regional geographic location (Northeast,
Midwest, South, and West)?
H01: There is no significant association between emergency services use
(accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
Ha1: There is a significant association between emergency services use
(accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
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Data Analysis Plan. Chi-Square was the analysis used to explore if there was a
significant association of the dependent variables (emergency visits) as an indicator of
accessibility to health care as the geographic regions Northeast, Midwest, South, and
West (independent variables) change.
RQ2: Is there an association between the number of emergency department visits
(disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD
treatment?
H02: There is no significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
Ha2: There is a significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
Data Analysis Plan. Chi-Square was the analysis used to explore if there was a
significant association of the dependent variables (emergency visits) an indicator for
disease management as the geographic regions Northeast, Midwest, South, and West
(independent variables) change. The significance of the association was shown for the
number of emergency visits and mortality rates in accordance to each region and the
strength of the relationship.
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RQ 3: Is there an association between hydroxyurea approval and SCD mortality
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in
2006 (16 years later) and 2011 (21 years later)?
H03: Hydroxyurea approval does not have a significant association on mortality
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South,
and West) in 2006 (16 years later) and 2011 (21 years later)?
Ha3: Hydroxyurea approval has a significant association on mortality rates in
adults with SCD in relation to geographic location (Northeast, Midwest, South, and
West) in 2006 (16 years later) and 2011 (21 years later)?
Data Analysis Plan. Chi-Square analysis was used to statistically examine if
there was a significant association regionally for deaths rates among SCD patients. The
regional geographical locations in the Northeast, Midwest, South, and West (independent
variable) and the effect on the mortality rates (dependent variable) were compared
numerically.
Threats to Validity
Threats to external validity from the use of secondary data would include the
accurateness and completeness of the information provided by the participating states.
Limitations could be applied by specific states as to how the data could be used and the
information in the dataset could be eliminated. Internal validity could be compromised
with data input errors and coding. Threats to statistical conclusion validity were avoided
by choosing a valid sampling method and meeting the assumptions of the statistical tests
used increased the validity of the results. Threats to validity in HCUP datasets were
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addressed using edit procedures and were described in the procedures, recruitment, and
data collection section. The editing process is annual and conducted prior to release of
datasets to counteract the effects of threats to internal and external validity.
Ethical Procedures
An online HCUP data use tutorial and application were filed acknowledging the
privacy and confidentiality of using the datasets with existing private records or
documents. The agreement to access the HCUP datasets involved compliance with
HIPAA guidelines for privacy and confidentiality of the patients and the institutions. The
data has HCUP encrypted coding to protect the identity (Agency for Healthcare Research
and Quality, 2012). Coding that identifies the institution was eliminated from the dataset.
Once the data was received, the targeted population was recoded by diagnosis using the
auto recode function in SPSS. Location was identifiable by regional geographic location
(Northeast, Midwest, South, and North without the input of zip codes. In addition, the
data was stored in a file on a password locked home computer that is used solely by the
researcher. According to publications of the Office of Research and Integrity, U.S.
Department of Health and Human Services, data storage does not have a time and amount
limitation for storage, unless the research is funded and the researcher must allow for the
storage requirements of the funding institution. The HCUP billing and discharge data that
was used for this study will be destroyed using a software produce such as, Eraser or
CyberScrub after five years of maintenance.
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According to the guidelines from Walden University (2010A), the Walden
University IRB application was filed and approved requesting permission to conduct the
research. The information requested on the application included a description of the
•

proposed research,

•

research stakeholders and partners,

•

benefits of the research,

•

potential risks and conflict of interest,

•

confidentiality and data integrity,

•

tools used for data collection, and

•

a description of the study participants.

The Potential Risk and Benefits form in the IRB application described opportunities for
disclosure that could compromise privacy, confidentiality, and cause unintended effects
to others. The goal of the review board was to ensure that Walden University is in
compliance with Federal regulations and university ethical standards (Walden University,
2010A).
Summary
Chapter 3 provided a description of the targeted population, datasets, research
design, and instrumentation that were used to examine the research questions with
reliability and validity. In addition, ethical concerns, confidentiality, and privacy have
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been acknowledged. A numerical description of the population was used along with a
quantitative retrospective method in a comparative study to describe the association
between the variables with statistical analysis. The retrospective correlational design
required a review of the literature for the identification of variables that could affect
outcomes in SCD, in order to identify outcomes and their relationship to the changes.
The goal was to explore whether the independent variable has influenced the dependent
variables and the effects of covariates on the outcomes. The approach used to address the
research questions involved the use of dependent and independent variables, and
covariables to describe the correlation of geographic locations to emergency department
visits (accessibility and disease management), and mortality using HCUP data. In
Chapter 4 there is a description and significance of the findings from the statistical
analysis.
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Chapter 4: Results
Introduction
The purpose of this research study stood to compare the effects of geographic
locations regionally, emergency department visits, and deaths from SCD using Chi
Square. The statistical analyses explored the relationship between the independent
variable (regions) and dependent variables (ED visits and mortality). The targeted
population was adults age 21 years plus with SCD HbSS in the United States. In previous
research barriers to care for SCD patients have been identified in the areas of
accessibility, disease management, stigmas, and quality of care (Anderson et al., 2014;
Brousseau et al., 2010; Haywood et al., 2013; Smith et al., 2011; Ware, 2010). NIS 2006,
NIS 2011, NEDS 2006, and NEDS 2011 HCUP, AHRQ datasets were used to explore
regional differences in health care and health outcomes for sickle cell patients at 16 and
21 years after the approval of hydroxyurea for treatment.
Chapter 4 provides a description of the population characteristics by region for the
targeted sample. Statistical analyses were used to determine the association of regions,
ED visits, and mortality, and answer the research questions. Decisions were made to
reject or accept the null hypotheses based on those findings. The research questions and
hypotheses that were used to guide the study included:
RQ1: Is there a significant association between emergency services use
(accessibility) among adults with SCD and regional geographic location (Northeast,
Midwest, South, and West) represented by 46 states in the United States from the HCUP
database.
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H01: There is not a significant association between emergency services use
(accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
Ha1: There is a significant association between emergency services use
(accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
RQ2: Is there an association between the number of emergency department visits
(disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD
treatment?
H02: There is no significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
Ha2: There is a significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
RQ3: Is there an association between hydroxyurea approval and SCD mortality
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in
2006 (16 years later) and 2011 (21 years later)?
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H03: Hydroxyurea approval does not have a significant association on mortality
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South,
and West) in 2006 (16 years later) and 2011 (21 years later).
Ha3: Hydroxyurea approval has a significant association on mortality rates in
adults with SCD in relation to geographic location (Northeast, Midwest, South, and
West) in 2006 (16 years later) and 2011 (21 years later).
Data Collection
The datasets for the research were obtained from HCUP, AHRQ after Walden
IRB approval. Health Care Utilization Project collects administrative data annually from
participating partners and the data used for this study was collected from January 1, 2006
to December 31, 2006 and January 1, 2011 to December 31, 2011. The steps for
obtaining the datasets and the methods used by HCUP to collect data were discussed in
Chapter 3. The dataset for NIS has over 8 million cases and NEDS represents over 27
million cases. The cases from the datasets that met the inclusion criteria for this study
were weighted to make national estimates and included NIS 2006 (N=67,214), NIS 2011
(N=80,040), NEDS 2006 (N=164,698), and NEDS 2011(N=215,296). The variables were
selected from the datasets as demonstrated in Chapter 3, Figure 3.
Discrepancies in Data Collection
During the course of the analysis phases, there were changes made to the research
plan that were uncontrollable factors. The following changes were made to the research
plan following:
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•

Race was eliminated in the NEDS files by HCUP because of nonreports of race
by the states that followed regulatory mandates; race was reported in the NIS files
and used in the study to describe the population. NIS 2011 showed that 93.9% of
patients diagnosed with SCD HbSS were African American (Table 5).

•

Black was used to describe the race for people of subSaharan African descent in
the HCUP data files, for this study African American has been used instead of
black.

•

In order to encompass the majority of sickle cell HbSS cases, the diagnosis codes
used in the study were expanded to include 282.60 (nonspecific sickle cell
anemia) which is used when the genotype is not known, 282.61 sickle cell anemia
HbSS without crisis, and 282.62 (sickle cell anemia HbSS with crisis);

•

The number of medical record recorded diagnoses was expanded from using only
the primary and secondary diagnoses (diagnoses 1and 2), to include diagnoses 1
through 5. This change was made to capture the diagnosis of SCD from the billing
invoices when other medical and surgical conditions received billing priority,
such as pneumonia or a cholecystectomy.

Descriptive and Demographic Characteristics
The population sizes for the research were presented in four datasets, NEDS 2006,
NEDS 2011, NIS 2006 and NIS 2011 files, containing the subgroup of sickle cell patients
selected for this research. Included was the age group of 21 plus years with diagnoses 1
through 5 with the ICD-9-CM Code of 282.60 (nonspecific sickle cell anemia), 282.61
(HbSS sickle cell anemia without crisis), and (282.62 HbSS sickle cell anemia with
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crisis). Statistical analyses were performed on the SCD subgroup to describe the
population. The descriptive and demographic characteristics are shown in Table 2, Table
3, Table 4, and Table 5. The NEDS datasets were used to measure ED visits and NIS
datasets were used to measure inpatient hospital admissions. All data were weighted for
analyses with the application of discharge weights provided in the datasets to predict
national estimates.
The weighted sample size generated from HCUP data files allowed for
generalizability of the observed ED visits nationally. The inclusive population weighted
sample size for NEDS 2006 N=164,698 (Table 2), and NEDS 2011 N=215,296 (Table 3).
The largest SCD sample population was represented in the NEDS 2011 dataset. The
sample was comprised of 42% males and 58% females with 47% from the low income
quartile. Medicare and Medicaid were identified as the primary insurance for 35% and
42%, respectively. Regionally, 45% of the population lived in the South (Table 3). The
HCUP datasets represent 67% of the sampled sickle cell population in the United States.
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Table 2
NEDS 2006 Sample Descriptive Demographic Characteristics (weighted)
Variable

n=Frequency

Gender
Male
Female
Race (not reported)
Median Household Income
$1-$35,999
$36,000-$44,999
$45,000-$58,999
$59,000+
Hospital Region
Northeast
Midwest
South
West
Expected Primary Payer
Medicare
Medicaid
Private
Self-pay
No charge
Other
Disposition from Emergency Department
Did not die
Died in ED
NEDS 2006 Total N= 164,698

73,201
91,497

81,381
42,172
24,545
13,403
25,300
23,190
98,984
17,230
49,218
72,195
25,413
13,886
1,046
2,557
157,375
49

Valid
Percent

Mean

Standard
Deviation

100.0
44.4
55.6

.56

.497

100.0
48.0
21.0
19.8
11.2
100.0
15.4
14.1
60.1
10.5
99.8
29.9
43.8
15.4
8.4
.6
1.6
100.0
99.8
.0

1.81

.976

2.66

.861

2.11

1.043

.56

.497

71
Table 3
NEDS 2011 Sample Descriptive Demographic Characteristics (weighted)
Variable

n= Frequency

Gender
Male
Female
Race (not reported)
Median Household Income
$1-$38,999
$39,000-$47,999
$48,000-$62,999
$63,000+
Hospital Region
Northeast
Midwest
South
West
Expected Primary Payer
Medicare
Medicaid
Private
Self-pay
No charge
Other
Disposition from Emergency Department
Did not die
Died in ED

33,492
46,549

99,917
52,266
38,651
18,907
43,447
35,602
122,695
13,552
70,262
91,877
30,884
17,574
763
3,427
215,254
41

Valid
Percent

Mean

Standard
Deviation

100.0
41.8
58.2

.001

.497

100.0
46.4
24.3
18.0
8.8
100.0
20.2
16.5
57.0
6.3
99.8
35.2
42.1
16.0
4.2
.3
2.0
100.0
99.8
.0

1.81

.976

3.00

.912

1.98

1.017

.56

.497

NEDS 2011 TOTAL N= 215,296

The weighted sample size generated from the HCUP data files allows for
generalizability of the observations nationally. The inclusive population weighted sample
size for NIS 2006 was (N=67,214) [Table 4] and NIS 2011 (N=80,040) [Table 5] for
inpatient hospital admissions, representing 67% of the sickle cell anemia HbSS
population nationally. The largest sample size was the NIS 2011 data comprised of 42%
males and 58% females, with 48% from the low income quartile. Medicare and Medicaid
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were identified as the primary insurance for 35% and 42% of the population. Regionally,
46% of the population lived in the South (Table 5).
Table 4
NIS 2006 Sample (weighted) descriptive demographic characteristics
Variable

n=Frequency

Gender
Male
Female

28,166
38,987

White
Black
Hispanic
Asian or Pacific Islander
Native American
Other
Median Household Income
$1-$35,999
$36,000-$44,999
$45,000-$58,999
$59,000+
Hospital Region
Northeast
Midwest
South
West
Expected Primary Payer
Medicare
Medicaid
Private
Self-pay
No charge
Other
Disposition from Hospital
Did not die
Died

806
46,205
1,835
48
41
675

Race

NIS 2006 Total N= 67,214

32,208
15,882
10,810
6,469
17,657
13,242
30,799
5,517
21,614
28,659
11,584
2,964
536
1,805
66,777
416

Valid
Percent
100.0
41.9
58.1
100.0
1.6
68.7
2.7
.1
.1
1.0
100.0
49.3
24.3
16.5
9.9
100.0
26.3
19.7
45.8
8.2
32.2
42.6
17.2
4.4
.8
2.7
100.0
99.4
.6

Mean
.58

Standard
Deviation
.493

1.87

1.018

2.07

1.081

.01

.078
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Table 5
NIS 2011 Sample (weighted) Descriptive Demographic Characteristics
Variable

n = Frequency

Gender
Male
Female

33,492
46549

White
Black
Hispanic
Asian or Pacific Islander
Native American
Other
Median Household Income
$1-$38,999
$39,000-$47,999
$48,000-$62,999
$63,000+
Hospital Region
Northeast
Midwest
South
West
Expected Primary Payer
Medicare
Medicaid
Private
Self-pay
No charge
Other
Disposition from Hospital
Did not die
Died

936
70,511
1,773
192
27
1,682

Race

37,560
16,453
15,517
8,753
13,829
13,663
36,651
6,538
28,185
33,698
12,849
3,396
214
1,637
79,683
336

Valid
Percent

Mean

Standard
Deviation

100.0
41.8
58.2
100.0
1.3
93.9
2.4
.3
.0
2.2
97.7
48.0
21.0
19.8
11.2
100.0
26.3
19.7
45.8
8.2
99.8
35.2
42.1
16.0
4.2
.3
2.0
100.0
99.6
.4

.58

.493

2.11

.630

1.94

1.059

2.213

1.175

1.98

1.017

.00

.065

NIS 2011 N = 80,040

The variables hospital disposition (dependent) and hospital region (independent)
did not meet the assumptions for the proposed regression analysis for normality and
homoscedasticity. Homoscedasticity was evaluated with the Levene’s test (p < .001). The
variances were not equal across the sample. The sample met the assumptions for Chi-
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Square analysis. The dependent and independent variable were categorical and were
measured at a nominal level. The dependent and independent variables consisted of two
or more categories.
Results
Chi-Square analysis was used to determine the relationship between hospital
region (independent) and ED visits and mortality (dependent) variables. The assumptions
that were met included the variables were categorical and consisted of two or more
categorical independent groups. The predetermined confidence interval was 95% and p
value was <0.05 for the statistical analysis. The NEDS 2006 and NEDS 2011 datasets
were analyzed to respond to research questions number 1and 2. The NIS 2006 and NIS
2011 datasets were analyzed to answer research question number 3.
Research Question 1
RQ1: Is there a significant association between emergency services use
(accessibility) among adults with SCD and regional geographic location (Northeast,
Midwest, South, and West)?
H01: There is no significant association between emergency services use
(Accessibility) and the regional geographical location (Northeast, Midwest, South, and
West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
Ha1: There is a significant association between emergency services
use(accessibility) and the regional geographical location (Northeast, Midwest, South, and
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West) represented by 46 states in the United States from the HCUP database in adults
with SCD.
The NEDS 2006 with a sample size of N=164,704 was significant for an
association between regions and emergency services use Pearson chi-square x (21) =
5331.293, p =. 000 (Table 6, Figure 6). The strength of the association was weak; Phi
(.180), p = .000 and Cramer’s (.104), p = .000 (Table 7). The NEDS 2011 with a sample
size of N= 215,132 was significant for an association between regions and emergency
services use Pearson chi-square x (3) 44.502, p =. 000 (Table 6, Figure 6). The strength
of the association was weak; Phi (.014), p = .000 and Cramer’s (.010), p = .000 (Table 7).
Research Question 2
RQ2: Is there an association between the number of emergency department visits
(disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD
treatment?
H02: There is no significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
Ha2: There is a significant association in the number of emergency department
visits (disease management) for adults with SCD in the four regions (Northeast, Midwest,
South, and West) 16 and 21 years after FDA approval of hydroxyurea for SCD treatment.
The NEDS 2006 data was significant for an association between regions and
emergency services use Pearson chi-square x (21), = 5331.293, p = .000 (Table 6, Figure
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6). The strength of the association was weak; Phi (.180), p = .000 and Cramer’s (.104), p
= .000 (Table 7). The NEDS 2011 data was significant for an association between regions
and emergency services use Pearson chi-square x (3) 44.502, p = .000 (Table 6, Figure 6).
The strength of the association was weak; Phi (.014), p = .000 and Cramer’s (.010), p =
.000 (Table 7).
Table 6
NEDS 2006, NEDS 2011 Chi-Square Tests
NEDS 2006
Value

df

Asymptotic Significance
(2-sided)

Pearson Chi-Square

5331.392 21

.000

Likelihood Ratio

6876.872 21

.000

Linear-by-Linear Association

903.557

1

.000

N of Valid Cases

164,704
Value

df

Asymptotic Significance
(2-sided)

44.502
41.671
215,132

3
3

NEDS 2011

Pearson Chi-Square
Likelihood Ratio
N of Valid Cases

.001
.001
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Table 7
NEDS 2006 and NEDS 2011 Chi-Square Symmetric Measures (weighted)
NEDS 2006

Value

Approximate Significance

Nominal by Nominal Phi
.180
.000
Cramer’s V
.104
.000
N of Valid Cases
164,704
NEDS 2011
Value Approximate Significance
Nominal by Nominal Phi
.014
Cramer’s V
.010
N of Valid Cases
215,132

.000
.000

70%
60%
50%
40%
30%
20%
10%
0%
Northeast

Midwest

South

West

NEDS 2006

15%

14%

60%

11%

NEDS 2011

20%

17%

57%

6%

Figure 6. NEDS 2006 and NEDS 2011 Chi-Square significant association for emergency
visits by region
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Research Question 3
RQ 3: Is there an association between hydroxyurea approval and SCD mortality
rates in adults in relation to geographic location (Northeast, Midwest, South, and West) in
2006 (16 years later) and 2011 (21 years later)?
H03: Hydroxyurea approval does not have a significant association on mortality
rates in adults with SCD in relation to geographic location (Northeast, Midwest, South,
and West) in 2006 (16 years later) and 2011 (21 years later)?
Ha3: Hydroxyurea approval has a significant association on mortality rates in
adults with SCD in relation to geographic location (Northeast, Midwest, South, and
West) in 2006 (16 years later) and 2011 (21 years later)?
There was significant association between mortality and geographic location for
patients with SCD for NIS 2006 data. Pearson chi-square x (3), N= 17.866, p = .000
(Table 8, Figure 7). The strength of the association was weak; Phi and Cramer’s V N=
67,193 (.016), p = .000 (Table 9). The association between mortality and hospital regions
was significant in the data from NIS 2011 with Pearson chi-square x (4), N= 20.663, p =
.000 (Table 8, Figure 7). The strength of the association was weak; Phi and Cramer’s V
N= 80,019 (.016), p = .000 (Table 9).
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Table 8
NIS 2006, NIS 2011 Chi-Square Tests (weighted)
NIS 2006
Value

Pearson Chi-Square
17.866
Likelihood Ratio
17.889
Linear-by-Linear Association 5.643
N of Valid Cases
67,193

df Asymptotic Significance
(2-sided)
3
3
1

NIS 2011

Value

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

20.663 4
19.892 4
7.242 1
80,019

.000
.000
.018

df Asymptotic Significance
(2-sided)
.000
.001
.007

Table 9
NIS 2006 and NIS 2011 Chi-Square Symmetric Measures (weighted)
NIS 2006

Value

Approximate Significance

Nominal by Nominal Phi
.016
.000
Cramer’s V
.016
.000
N of Valid Cases
67,193
NIS 2011
Value Approximate Significance
Nominal by Nominal Phi
.016
Cramer’s V
.016
N of Valid Cases
80,019

.000
.000

80
40%
35%
30%
25%
20%
15%
10%
5%
0%
NIS 2006
NIS 2011

Northeast
14%
8%

Midwest
9%
5%

South
35%
19%

West
4%
3%

Figure 7. NIS 2006 and NIS 2011 Chi-Square significant association for inpatient
dispositions by region, died in hospital
Summary
I designed the study to explore the effects of geographical regions on the health of
sickle cell anemia patients 16 and 21 years after the approval of hydroxyurea by the FDA
for treatment. Inpatient deaths and ED visits were used as indicators to document changes
in health and health outcomes. The NEDS 2006, NEDS 2011, NIS 2006, and NIS 2011
datasets were tested separately with Chi-Square. The results revealed a significant
association between ED visits (dependent variable), deaths (dependent variable), and
regions (independent variable). The associations were weak according to Phi and Cramer
results. ED visits increased in the Northeast (N=43,447), Midwest (N=35,603), and South
(N=122,695), when compared to 2006 when ED visits in the Northeast were (N=25,300),
Midwest (N=23,190), and South (N=98,984) [Table 10]. The West showed a decrease in
ED visits shows a summary of inpatient deaths and emergency department visits by
region results for are in 2011 (N=13,552) and 2006 showed an increase (N=17,230)
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[Table 10]. The Northeast, Midwest, South, and West had more deaths in 2006 than
2011.
Table 10
NIS 2006, NIS 2011, NED 2006, and NEDS 2011 Summary of inpatient deaths and
emergency department visits by region

NEDS 2006
NEDS 2011
NIS 2006
NIS 2011

ED Visits
ED Visits
Inpatient Deaths
Inpatient Deaths

Northeast

Midwest

South

West

25,300
43,447
93
62

23,190
35,602
62
37

98,984
122,695
233
152

17,230
13,552
28
24

The results for the research questions are
• RQ1: There was a significant association between ED visits (accessibility) and
geographic regions in the United States.
• RQ2: There was a significant association between ED visits (disease
management) and geographic regions in the United States.
• RQ3: There were decreased mortality rates in the four regions of the United
States (Northeast, Midwest, South, and West) 13 years after the FDA approved
Hydroxyurea for treatment.
Relative to the findings revealed in Chapter 4, Chapter 5 includes a
discussion of the future research, relevance of the findings, limitations of the study,
and the social change that could occur to improve the health and health outcomes of
patients with sickle cell anemia, 21 years and older.
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Chapter 5: Discussion
Introduction
This study was used to document the effects of geographical locations on the
health and health outcomes of SCD patients, 21 years and older, 16 and 21 years after
FDA approval of hydroxyurea for the treatment of the disease. The findings of the study
are important because hydroxyurea is the only drug approved by the FDA as a preventive
measure to counteract the effects of SCD. Hydroxyurea increases and improves the
ability of the body to produce fetal hemoglobin which is decreased or nonexistent for
sickle cell patients (McGann & Ware, 2011). The increased production of fetal
hemoglobin decreases the sickling of the red blood cells, thereby decreasing painful
episodes, organ damage, and increases the life span (McGann & Ware, 2011). Medically,
it is recommended that hydroxyurea should be a standard of care for patients with SCD
by WHO and the NHLBI (Moussavou et al., 2004).
Emergency visits and inpatient hospital deaths were measured regionally with
HCUP datasets; NEDS 2006 and NEDS 2011 were used to document accessibility and
disease management (emergency visits) regionally and NIS 2006 and NIS 2011 were
used for health outcomes (deaths) regionally. The results for the years were compared to
document regional changes that could indicate accessibility and disease management.
The findings using Chi-Square analysis showed that the relationship between regions,
emergency department visits, and deaths was significant. Phi and Cramer’s revealed that
the strength of the relationships was weak.
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The association between ED visits (accessibility and disease management) and
regions was discovered in RQ1 and RQ2 in this study and was significant based on ChiSquare results. RQ3 disclosed a significant association between deaths and regions using
Chi-Square.
Interpretation of Findings
Increased frequency of emergency visits found in this study were consistent with
previous studies by (Brousseau et al., 2010; Wolfson et al., 2012) showing patients with
SCD with high rates of emergency department visits (accessibility to care and disease
management). Regionally emergency department visits increased from 2006 to 2011 with
the NEDS datasets, except the West showed a decrease (Table 11).
Table 11
ED Visits 2006 and 2011
Northeast
Midwest
South
West

ED Visits 2006
25,300
23,190
98,984
17,230

ED Visits 2011
43,447
35,602
122,695
13,552

The availability and accessibility of care were the reasons identified that sickle cell
patients seek care in emergency departments (Bundy et al., 2011; Glassberg et al., 2012;
Haywood et al., 2013). Pain management was found to be the primary reason sickle cell
patients sought care in the emergency department (Tanabe et al., 2010). The alternate
hypotheses for this study were supported for Research Questions 1 and 2; there is a
significant association between emergency visits (accessibility and disease management)
and regional location (Northeast, Midwest, South, and West) in the United States.
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Mortality rates for sickle cell patients showed regional decreases in this study from 2006
to 2011(Table 12).
Table 12
NIS Recorded Deaths
Northeast
Midwest
South
West

Deaths 2006
93
62
233
28

Deaths 2011
62
37
152
24

According to a publication by Bender and Seibell (2014), ages 55 years and older would
be the life expectation for a subset SCD patients and high rates of morbidity would
persist. Platt et al. (1994) reported that the median age of death was 42 years (males) and
48 years (females). The number of sickle cell deaths by region, which was not found in
previous research, was explored in this study; age at the time of death was not examined.
The alternate hypothesis was supported in the findings; there was a significant association
with SCD mortality rates and the four regions in the United States 16 and 21 years after
the approval of hydroxyurea.
Limitations of the Study
The study population for generalization was limited to adults 21 years and older
with SCD (nonspecific 282.60), HbSS (without crisis 282.61), and HbSS (with crisis
282.62) by ICD-9-CM Codes. The analysis was performed 16 and 21 years after the
approval of hydroxyurea in 1990 by the FDA, however, the consumption of hydroxyurea
was not measured. The results of the study provide an overall view of the adult sickle cell
population in terms of emergency visits (accessibility and disease management) and
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mortality (health outcomes) by region for the years 2006 and 2011. Limitations would be
the information reported and restrictions on data use that was applied by specific states;
the information could have been eliminated in the dataset, such as race, and the number
of incidents per region could not be reported if the frequency was 10 or less. Internal
validity could be compromised with data input errors and coding.
Recommendations
Sickle cell patients 21 years and older with HbSS, the most severe genotype that
is predominate among people of subSaharan African descent living in the United States
that used emergency services in 2011 were:
•

Low income (46.4%) (Table 3).

•

Insured by Medicaid (42.1%) (Table 3).

•

Lived in the Southern region of the United States (57%) (Table 3).

There were differences in the emergency visits and deaths among the regions, the South
had the highest rates in emergency visits; South (122,695), Northeast (43,447), Midwest
(35,602), and West (13,552). Future research could focus on the Southern region of the
United States to explore disease management and accessibility to care. Increased
emergency visits could be reduced with the implementation of standardized treatment
regimens for SCD patients, thereby reducing the costs for frequent emergency visits for
treatments (Andemariam et al., 2014; Epstein et al., 2006; Hague & Telfair, 2000; Kauf
et al., 2009; Wolfson et al., 2012).
Comparatively, the mortality rates in 2011 were higher in the South (152) than the
Northeast (62), Midwest (37), and West (24). Mortality may possibly be investigated
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further to explore the age groups, treatment regimens, and whether there was an increase
or decrease in morbidities for adults with SCD. Additional future research could
document the age of death for males and females with SCD HbSS phenotype, and note if
there is an increase in life span for 43 years (males) and 48 years (females), with the
inclusion of the role of hydroxyurea in the sample population.
Implications
An indicator for accessibility, disease management, and severity of disease is the
frequency of sickle cell patients seeking care in emergency departments Bergman &
Diamond, 2013; Haywood et al., 2013). The effect on accessibility and disease
management could be initiated by a lack of continuity of care from private physicians.
Accessibility to care is affected by insurance coverage; the majority of patients have
government funded insurance (Medicaid) which is not widely accepted by private
physicians because of the low payment fees (Brousseau et al, 2010; Jan et al., 2013;
Wolfson et al., 2012). Providers of healthcare could be educated on the Sickle Cell
Treatment Act of 2003-2004 which provides for matched funding on treatment costs of
Medicaid covered SCD patients (108th Congress 1st Session, 2004). Education on a
chronic disease self-management care model could benefit SCD improvements in disease
management and health outcomes regionally (Jenerette & Murdaugh, 2008). The
socioecological model was the framework used to integrate the effects of internal and
external factors on the health and health outcomes of sickle cell patients. Factors that
would require consideration for education and treatments would be income level,
insurance status, and the incorporation of the region where the patients reside.
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The concepts of the Donabedian model for quality in healthcare used with the
guidelines of a chronic disease self-care management model could be effective in
improving health outcomes and quality of care for sickle cell patients. Providers of care
would communicate with patients in regards to laboratory tests values and discuss
treatment regimen decisions collaboratively. A chronic disease self-care management
model specific for SCD would include patient awareness of norms for individual
hemoglobin and hematocrit levels, date of last blood transfusion, routine medications,
surgical and medical history, and effective pain management regimen. The elements of
SCD self-care management can contribute to the concepts of providers of care and health
outcomes in the Donabedian model for quality health care. Educating providers and
patients would be beneficial in introducing a chronic disease self-care management
model and contribute to the effectiveness of the process.
Improvements in education and increased SCD awareness would be the initial
steps needed for social change to occur and benefit advances in disease management,
health care, and health outcomes. Social change implications could involve the creation
of a group of SCD patients with better quality health and quality of life. The changes
would increase the probability of progress academically and in the workforce.
Future research might include a discussion on qualitative and mixed methods to
explore the use of hydroxyurea by the adult population and the development of education
for health care professionals and sickle cell patients. The results of this study could lead
to improving education in collaboration with a SCD chronic disease self-care
management model for health care providers, patients, families, and medical

88
organizations. Demographically the majority of the sickle cell population congregated in
the South with a majority in low income quartiles, and high rates of government issued
insurance. The Southern region had increased deaths and ED visits that exceeded the
other regions and could be the alpha site to target an educational program. The National
Sickle Cell Disease Act of 1972 provides funding to disseminate educational materials
for provider and patient education, and grants for research on controlling and treating the
disease (American Society of Hematology, 2008).
Conclusion
Since SCD was discovered over 100 years ago, treatment regimens have been
geared toward symptoms caused by the condition; opioids for pain management, blood
transfusions for severe sickling and painful crisis, surgical interventions to remove
damaged organs, and hemodialysis to replenish renal function for damaged kidneys.
Since 1990, hydroxyurea is the only drug approved by the FDA for preventive treatment,
yet research has shown that it is not widely prescribed by physicians or used by patients.
Increased frequency of emergency department visits demonstrated in this study indicate a
need for improvements in disease management. There were decreased frequencies in
death rates in the results that should be investigated further concerning comorbidities and
treatment regimens.
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